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DEVELOPING METHODOLOGY FOR INCORPORATION OF BETA-AMINO ACIDS INTO 
PROTEIN TERTIARY STRUCTURES 
 
George Andrew Lengyel, M.S. 
 
University of Pittsburgh, 2011 
 
 
The goal of this project is to explore methodologies applicable to introducing β-amino acid residues into 
natural protein sequences with well-defined tertiary structures while maintaining the folded structure of 
these natural sequences.  Hybrid α/β-peptides synthesized with β-amino acids have additional rotational 
freedom of their backbone and also have increased resistance to proteolysis relative to natural α-peptides.  
16 unnatural β-amino acids with varied stereochemistry and torsional restraints were synthesized using a 
variety of published literature methods.  A peptide model system known to fold into a β-hairpin secondary 
structure in aqueous solution was chosen for substitution with the unnatural residues at two positions.  
Using Fmoc solid-phase peptide synthesis, 16 hybrid α/β-peptides as well as 16 unfolded control peptides 
were synthesized and studied by 2D NMR.  Using the NMR data obtained from this study, the mutant 
peptides were analyzed for indications of folded population.  Three peptides showed a high degree of 
folded population: those including a β3-amino acid and two including the enantiomers of a trans-
disubstituted-β2,3-amino acid.  NOE-derived distance restraints were established and high-resolution 3D 
structures of these peptides were calculated.  Using these structures, it was found that the peptide 
substituted with (2R, 3S)-3-amino-2,4-dimethylpentanoic acid most closely emulated the hairpin structure 
of the model system.  Currently, work is ongoing to determine the effect of side-chain functionalization 
and substitution pattern on the folding of larger protein systems. 
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1.0. INTRODUCTION 
 
 
 
 
 The goal of this project is to explore methodologies applicable to introducing β-amino acid 
residues into natural protein sequences with well-defined tertiary structures while maintaining the folded 
structure of these natural sequences.  β-Amino acids contain an additional carbon atom in the backbone 
relative to α-amino acids, resulting in several unique characteristics.    
 First, β-residues can improve peptide resistance to proteolytic degradation.2  Hybrid α/β-peptides, 
peptides which contain mixtures of α- and β-residues, can have dramatically increased half-lives 
compared to natural peptides when exposed to proteases.  This increased resistance to degradation makes 
these hybrid peptides valuable as drug scaffolds for biomedical research.   
 Second, the additional carbon atom in the backbone of β-amino acids adds an extra degree of 
rotational freedom and can affect folded conformation and flexibility of the peptide sequence.  In terms of 
conformation, the additional carbon can influence both the hydrogen bonding pattern and the orientation 
of the side-chains of residues in a secondary structure.  As folded structure determines function, change of 
structure resulting from β-residue insertion can lead to a loss of the function sought from a particular 
therapeutic.  There is little research to date in the area of β-residue incorporation in larger proteins with 
tertiary folded structures; the vast majority of research has been in the area of peptides that fold into 
helical secondary structures and tight turns.3  There is a significant gap in the study of inclusion of β-
residues in β-sheet and loop secondary structures, both of which are found in the tertiary structures of 
natural proteins. 
 It is the aim of this project to establish a general methodology for inclusion of β-residues that can 
be used in any number of proteins with well-defined tertiary structures.  In order to accomplish this goal, 
we plan to develop methodologies to incorporate β-residues into small peptides which form β-hairpins, 
structures containing two antiparallel strands connected by a short turn, usually two-to-four residues.  
2 
 
Once these methodologies have been established, they will be used to design and synthesize mutants of 
proteins with known tertiary structures including both sheet and helical elements.    
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2.0. BACKGROUND 
 
 
 
 
2.1. PROTEINS AS THERAPEUTICS 
 
 
Proteins, one of the core building blocks of biology, have many important functions including the ability 
to activate and inhibit cellular processes in the body.  Because of the ability of proteins to affect these 
processes, natural proteins or synthetic agents that mimic their structure are sought after as therapeutics 
where small molecule scaffolds fail.  One example of such a therapeutic is insulin, the first peptide drug 
licensed by the FDA, used for the treatment of diabetes.4  Therapeutic proteins such as insulin, unlike 
small molecule drugs, are highly specific in their targets and are oftentimes present in the body. These 
two factors make protein therapeutics less likely to promote unwanted immune responses, thereby making 
them attractive drug scaffolds. 
 One major drawback of the use of proteins as therapeutics, however, is their susceptibility to 
proteases naturally occurring in the body.  Degradation of therapeutic proteins in the body can lead to a 
need for multiple or increased dosages.  In order to decrease the susceptibility of therapeutics to 
proteolytic degradation, peptides with unnatural backbones have been employed.  For example, it has 
been shown that adding β-amino acids (analogs of natural α-amino acids containing an additional 
backbone carbon) to natural peptides can alter the electronics of peptidic bonds or disrupt recognition 
between proteases and the mutant peptide, thereby decreasing the rate of proteolytic degradation.2,5 
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2.2. FOLDAMERS 
 
 
Because of the ability of peptides with unnatural backbones to reduce the rate of proteolytic degradation, 
much effort has gone into designing peptidomimetics that maintain the same therapeutic function as 
natural proteins.  Folded structure determines function, so in order to maintain the same function as 
natural proteins, peptidomimetics need to be able to emulate the same folded structure as their natural 
analogs.  The search for compounds with unnatural backbones with predictable folded structure has led to 
the development of a class of compounds known as foldamers.  The term “foldamer” was coined by 
Samuel Gellman and is defined as, “any polymer with a strong tendency to adopt a specific compact 
conformation.”6  
 Many types of foldamers exist and most utilize building blocks similar to natural amino acids.  
One common type of monomer used in foldamer design is the β-amino acid (Figure 2.1A).  β-Amino 
acids contain an additional carbon in the backbone when compared to α-amino acids and can be 
substituted in various ways to generate β2-, β2-, or β2,3-amino acids.  Other types of monomers include the 
γ-amino acid (Figure 2.1B), and α- or β-peptoids (Figure 2.1C). 
 
 
 
 
 
 
 
Figure 2.1. Foldamer Building Blocks 
A 
B C 
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2.3. PEPTIDES WITH HOMOGENEOUS β-AMINO ACID BACKBONES 
 
 
The first studies of foldamers utilized β-amino acids to generate β-peptides, oligomers with homogeneous 
β-residue backbones.   One of the earliest studies of the folding patterns of these β-peptides involved 
inclusion of 2-aminocyclohexanecarboxylic acid (ACHC), shown in Figure 2.2.7   
 
 
 
 
 
 
 
 This cyclic monomer was chosen in order to reduce the extra flexibility in the monomeric 
backbone provided by the additional methylene unit found in β-residues (Figure 2.3).  By incorporating 
the backbone of a β-residue into a ring, the conformation of the β-residue is rigidified and free rotation is 
reduced.   
 
 
 
 
 
 
 
 
 
Figure 2.2. ACHC 
 
 
Figure 2.3. Rotatable Bonds in α- and β-Amino Acids  
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From the studies of ACHC, it was found that the trans form of the monomer could be used to build a 
monomeric hexamer that folds into a helical conformation in both solid state and in methanol (Figure 
2.4).   
 
 
 
 
 
 
 
Further studies showed that use of trans-aminocyclopentanecarboxylic acid (ACPC) (Figure 2.5) could 
be used to build a hexamer that folds into an alternate helical conformation under the same conditions as 
the ACHC hexamer.8  It has also been shown that by changing the conformation from trans to cis, an 
ACPC pentamer can adopt a sheet-like conformation in DMSO.9  
 
 
 
 
 
Figure 2.4. Solid State Conformation of trans-ACHC Hexamer 
Figure adapted from J. Am. Chem. Soc. 1996, 118, 13071.  Used with permission. 
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 Acyclic β-residues can adopt helical folding patterns as well; a hexapeptide made using β3-
residues adopts a left-handed helix secondary structure in pyridine and in methanol.10,11  Other  studies 
have shown that a hexapeptide made using β2-residues forms the opposite right-handed helix in 
methanol.12  
 Not only can peptides made entirely of β3-residues adopt helical conformations, they can also 
disrupt the growth of E. coli.13  In one study, a helical peptide made of repeating units of three β3-residues 
gave an IC50 value of 1.7 µM in regards to inhibiting bacterial growth.  Unfortunately, these same 
peptides were non-selective and gave an IC50 value of 2.6 µM in regards to hemolysis of red blood cells. 
 The ability of a peptide to adopt different secondary structure conformations depending on the 
subunits included in the peptide indicates that selectivity in the type of β-residues used in peptides can be 
used to promote desired secondary structures.   
 
 
2.4. PEPTIDES WITH HYBRID α/β-AMINO ACID BACKBONES 
 
 
Although able to adopt specific conformations based on monomers selection, peptides made exclusively 
from β-residues require a great deal of synthetic work in order to provide the β-residues used.  One 
solution to this problem is the use of oligomeric peptides containing both α- and β-residues.  The 
inclusion of β3-residues in both the turn and strand positions of a β-hairpin still allows folding in methanol 
(Figure 2.6), although inclusion of β3-residues reverses the hydrogen bond pattern.14-16  Work from the 
Gellman lab has shown that peptides made with alternating α-residues and ACPC residues can fold into 
helical conformations in methanol.17 
 
 
Figure 2.5. ACPC 
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 Arising from the idea that hybrid α/β-peptides can fold in predictable ways, recent research has 
examined the folding of hybrid peptides based on natural sequences.  Modifying a known peptide 
sequence with functionalized residues is known as “sequence-based design.”  With the intent of designing 
peptides that mimic the side-chain display and self-association properties of natural peptides, the Gellman 
lab used sequence-based design, replacing the residues on the hydrophilic faces (shown in bold below) of 
helical peptides GCN4-p1 and GCN4-pLI with functionalized β3-residues (Figure 2.7).18   
 
GCN4-p1 Ac-RMKQLEDKVEELSKNYHLENEVARLKKLVGER-OH 
GCN4-pLI Ac-RMKQIEDKLEEISKLYHIENELARIKKLLGER-OH 
 
 
 
Figure 2.6. Schematic of a Crystal Structure of a Hybrid α/β-Peptide that Forms a β-Hairpin 
Figure adapted from Proc. Natl. Acad. Sci. 2002, 99, 5160.  Used with permission. 
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Crystal structures solved for the α/β-mutants of the GCN4-p1 and GCN4-pLI peptides show that these 
peptides not only folded into helical conformations, but they also self-associated into trimeric and 
tetrameric bundles, respectively.  This finding is important because although GCN4-p1 normally forms a 
dimer, both mutants showed the ability to form a helix-bundle, a quaternary structure.  Further work with 
GCN4-p1 and GCN4-pLI has shown that a variety of α/β-backbone patterns, including substitution of 
specific β3-residues with cyclic β-residues, can further stabilize helix formation and generate quaternary 
structures encoded by the natural peptide sequences.19  
 
 
 
 
 
  
 
 
Figure 2.7. Crystal Structures of α/β-Mutants of GCN4-p1 and GCN4-pLI 
Figure adapted from J. Am. Chem. Soc. 2007, 129, 4178.  Used with permission. 
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2.5. HYBRID α/β-PEPTIDES AS POSSIBLE THERAPEUTIC AGENTS 
 
Based on the work with helix bundles, sequence-based design was later used to generate helical α/β-
peptides that block protein-protein binding interactions involved in HIV-cell fusion.20  Three copies of 
protein gp41 are found together on the HIV virion surface, each containing helices at the N- and C-
termini (Figure 2.8).21  During fusion of HIV with the cell membrane, the six helices found in the three 
copies of gp41 come together to form a six-helix bundle.  Peptides that mimic the C-terminal helices can 
bind to the N-terminal helices and effectively block membrane fusion and therefore HIV infection.   An 
α-peptide derived from HIV gp41 is a clinically used drug, enfuvirtide (Fuzeon). 
 
 
 
 
  
 
 
Figure 2.8. HIV-Cell Membrane Fusion 
Figure adapted from Cell 1998, 93, 681.  Used with permission. 
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Using a peptide sequence derived from the C-terminus of gp41, two hybrid α/β-peptides were synthesized 
using only β3-residues or a combination of β3- and cyclic-residues (Figure 2.9).  Based on binding 
studies, both hybrid peptides had similar or stronger binding than the natural peptide to the N-terminal 
sequence of gp41.  In addition to this, the hybrid containing β3-residues had a half-life of 14 minutes and 
the hybrid containing β3- and cyclic-residues had a half-life of 200 minutes when subjected to proteolysis 
by proteinase K.  These two values are much higher than the 0.7 minutes reported for the natural 
sequence.  Both hybrids also showed equal or greater HIV-infection inhibition compared to the natural 
sequence.  
 
 
 
 
 
 
 In another study, α-helical BH3 domains, which bind to proteins in the BCl-2 family that are 
involved in programmed cell death (apoptosis), were modified using functionalized β3-residues and 
sequence-based design.22   Several α/β-peptides were synthesized using the substitution pattern ααβαααβ 
and their binding to two members of the BCl-2 family studied.  Two of the hybrid peptides derived from 
 
Figure adapted from Proc. Natl. Acad. Sci. USA 2009, 106, 14751.  Used with permission 
 
Figure 2.9. Hybrid α/β-Peptides Used in HIV Binding Study 
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this substitution pattern demonstrated both increased binding and increased protease resistance compared 
to the natural peptide.   
 
 
2.6. MODEL SYSTEM GB1 
 
It is important to note that both of the studies above and other studies of hybrid peptides as therapeutics 
have relied on the α-helix as the target secondary structure for mimicry; little work has been done using β-
sheets or larger tertiary structures.  In fact, no rules have been established for the incorporation of β-
amino acids into proteins that contain β-sheets in aqueous solution, let alone incorporation of these 
residues into proteins with well-ordered tertiary structures.  These rules are important because the ability 
to mimic more complex folded structures will provide the ability to mimic more complex functions. 
 The goal of this project is to develop the strategies necessary to create unnatural backbone 
peptides that demonstrate the ability to form well-folded tertiary structures.  To this end, the protein GB1 
has been chosen as an initial target.  GB1 is a 56-residue protein derived from the B1 domain of group G 
Streptococcus and has been studied extensively.  Both the X-ray crystal structure23,24 and NMR 
structure24,25 have been solved and show that the protein is made up of an α-helix as well as two 
antiparallel β-sheets that come together to form a parallel β-sheet (Figure 2.10).   
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 Protein GB1 is an ideal target for several reasons.  First, because it is only 56 residues long, it can 
be synthesized using standard solid-phase peptide synthesis (SPPS) techniques.  GB1 can also be 
synthesized using protein expression by bacteria, but this expression limits the structure to inclusion of 
only α-amino acids.   Using SPPS allows great flexibility in both placement and variety of unnatural 
residues included; monomers synthesized in-house can be added to the structure with relative ease. 
 GB1 also includes a variety of secondary structures that can be modified with unnatural 
backbones using either pre-established rules, as in the case of the α-helix, or by rules we will design 
ourselves, in the case of β-sheet regions and the loop regions.  These structural elements can be modified 
individually or in various combinations to determine their effect on tertiary structure.  As the crystal 
structure of GB1 has been determined, crystal structures of mutants can be sought and then compared to 
the structure of the natural protein to determine the effects of the mutations on folded structure. 
 Finally, protein G, from which GB1 is a segment, has a high binding affinity for immunoglobin G 
(IgG).26  Competitive binding assays have been done using the GB1 domain chosen for our study.27  To 
determine whether or not our modifications will alter a protein’s function, we can also use competitive 
 
MTYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTYDDATKTFTVTE 
 
 
Figure 2.10. Structure of Protein GB1 
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binding assays to determine the effect of the backbone modifications implemented in our studies on the 
binding of protein GB1 mutants to IgG. 
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3.0: PROBING β-RESIDUE IMPACT ON β-SHEET FORMATION 
(This section based on the article published as J. Am. Chem. Soc. 2011, 133, 4246.)1 
 
 
3.1. RESULTS AND DISCUSSION 
 
3.1.1. β-Hairpin Model System 
 
Although GB1 is the long-term target for this study, in order to simplify the system and determine which 
specific β-residue substitutions are tolerated in a β-sheet, we began our investigations with a smaller 
system.  A sixteen-residue fragment, 1, found in the C-terminus of the GB1 protein, has been shown to 
form a β-hairpin in aqueous solution.28  A shortened derivative of 1, 2a, also demonstrates folded 
behavior under aqueous conditions.29  In peptide 2a, the loop is shortened to a tight D-Pro-Gly turn in 
order to encourage folding to a β-hairpin (Figure 3.1).30,31  
 
1  H-GEWTYD[DATK]TFTVTE-OH 
2a H-RWQYV[DPG]KFTVQ-NH2  
16 
 
 
 
 
3.1.2. β-Monomer Selection and Peptides Studied 
  Peptides were synthesized to examine a variety of possible β-residue substitutions in hairpin 
peptide prototype 2a (Figure 3.2).  Based on the established ability of β3-residues to form complex 
secondary structures, peptides were synthesized with both enantiomers of a β3-residue bearing an 
isopropyl side-chain (3a, 4a).  To determine the effect of side-chain placement and enhanced rigidity 
provided by additional substitutions, peptides were synthesized including both enantiomers of an 
isopropyl-bearing  β2-residue (5a, 6a), and all four stereoisomers of a disubstituted β2,3-residue (7a-10a).  
As cyclic β-residues have also shown the ability to promote secondary structure, they were also screened 
to determine the effects of stereochemistry and torsional restraint.  Peptides were prepared with both 
enantiomers of the trans-ACPC residue (11a, 12a), both enantiomers of the cis-ACPC residue (13a, 14a), 
both enantiomers of the trans-ACHC residue (15a, 16a), and both enantiomers of the cis-ACHC residue 
(17a, 18a).  Additionally, to provide unfolded controls, a variant of each of these 17 peptides was also 
synthesized with a D-proline to L-proline substitution in the turn (2b-18b). 
 
 
Figure 3.1. β-Hairpin Structure of Peptide 2a  
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3.1.3. Monomer Synthesis Methodology 
 Monomers used for peptide synthesis were prepared by modifications of a variety of literature 
methods.  β2-Monomers were synthesized using a diastereoselective Mannich reaction.32,33 Anti-β2,3-
monomers were produced from ring opening reactions of enantiomerically enriched lactams.34,35  Syn-β2,3-
monomers were generated from ring opening reactions of enantiomerically enriched thiazinones.36  Cis-
ACPC and cis-ACHC monomers were formed from ring opening reactions of enzymatically resolved 
lactams.37-39  Trans-ACPC and trans-ACHC monomers were synthesized following published protocols 
without modification.40,41  β3-Monomers were purchased in protected form.  Full experimental details can 
be found in the experimental section. 
 
2a      H-RWQYV[DPG]KFTVQ-NH2 
2b  H-RWQYV[LPG]KFTVQ-NH2 
3a-18a  H-RWXYV[DPG]KFXVQ-NH2 
3b-18b H-RWXYV[LPG]KFXVQ-NH2 
 
 
 
Figure 3.2. Peptides Studied 
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3.1.4. Fmoc-β2-Monomer Synthesis  
 
 
 
 
 
Fmoc-β2-monomers were synthesized using a diastereoselective Mannich reaction.32,33  Iminium-
precursor N,O-acetals 20a and 20b were synthesized by addition of formaldehyde to substituted amines 
19a and 19b.  Compounds 20a and 20b can generate iminium salts in situ; these salts were reacted in 
anhydrous methanol with isovaleraldehyde in a Mannich reaction to generate compounds 21a and 21b.  
The combination of organic catalyst used in the Mannich reaction and the stereochemistry of the chiral 
auxiliary is key to diastereoselectivity.  Using diphenylprolinol TMS ether in combination with 
compound 20a results predominantly in the formation of the (R),(R) diastereomer of compound 21a.  
Steric repulsion between the bulky TMS group and the benzyl groups of the iminium ion promotes attack 
of the iminium ion on the opposite face of the enamine (Figure 3.4).  
 
 
Figure 3.3. Synthesis of Fmoc-β2-Monomers 
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Using D-proline in combination with (S)-N,O-acetal 20b results predominantly in the (S),(S) diastereomer 
21b.  In this case, Coulombic attraction between the carboxylate and iminium ions dictate attack of the 
iminium ion on the same face of the enamine (Figure 3.5).   
 
 
 
 
  
 
 
Figure 3.4. Transition State in the Synthesis of Compound 21a 
  
 
Figure 3.5. Transition State in the Synthesis of Compound 21b 
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Aldehydes 21a and 21b were reduced with sodium borohydride to generate alcohols 22a and 22b.  
The benzyl groups were then removed from the amine by hydrogenolysis.42   A standard Fmoc 
protection43 was used to protect the amine followed by a Jones oxidation to yield the protected carboxylic 
acids 23a and 23b.     
 
3.1.5. Fmoc-anti-β2,3-Monomer Synthesis 
 
 
 
 
 
Fmoc-anti-β2,3-monomers 26a and 26b were synthesized by ring opening of enantiomerically enriched 
lactones.  Lactones 24a and 24b were synthesized using an enantioselective [2+2] cycloaddition.34  
Propionyl chloride was added slowly to a reaction mixture containing isobutyraldehyde, a cinchona 
alkaloid catalyst (either TMS-quinine or TMS-quinidine), LiClO4, and DIEA.  In a mechanism proposed 
by the Nelson group (Figure 3.7), the DIEA deprotonates the acid chloride, generating a ketene which 
reacts with the alkaloid catalyst to generate an enolate stabilized by the Lewis acid, LiClO4.  The 
quaternary amine coordinates with isobutyraldehyde to form a six-membered ring intermediate.  The 
 
 
Figure 3.6. Synthesis of Fmoc-Anti-β2,3-Monomers 
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intermediate results in a formal [2+2] addition between the aldehyde and ketene to generate the product 
lactone. 
 
 
 
 
 
 
 
 
The stereochemistry of the alkaloid catalyst directly determines the stereochemistry of the 
product; TMS-quinine results in the formation of 24a while TMS-quinidine results in the formation of 
24b.  Low yields were observed for both products, most likely due to volatility of the product as well as 
the steric repulsion between the isopropyl and methyl groups during ring formation.  It was also noted 
that a large amount of ketene dimer was formed during this reaction, suggesting that the lactone formation 
is not energetically favorable compared to alternative side-products. 
Lactones 24a and 24b were ring-opened using sodium azide in an SN2 reaction to form azido 
acids 25a and 25b.35  Several attempts were made to directly couple the azido acid monomers in solid-
phase peptide synthesis, but reduction of the azide functional group to an amine on solid support proved 
to be problematic.  In order to overcome the complications of azide deprotection, the azido acids were 
reductively hydrogenated in solution using Pearlman’s catalyst and hydrogen gas35 and then Fmoc 
protected to generate 26a and 26b.43 
 
 
 
Figure 3.7. Transition State of Lactone Formation 
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3.1.6. Syn-β2,3-Monomer Synthesis 
 
 
 
 
Fmoc-anti-β2,3-monomers 30a and 30b were synthesized using a ring opening of enantiomerically 
enriched thiazinones 29a and 29b.  O-butyl thiocarbamate 27 was formed by treatment of potassium butyl 
xanthate with chloroacetic acid and sodium hydroxide44 followed by addition of ammonium hydroxide.  
α-Amido sulfone 28 was then produced in a reductive amination by combining 27 with sodium para-
toluene sulfinate, isobutyraldehyde, and formic acid in water.36     
 To generate the enantiomerically enriched thiazinones, sulfone 27 underwent a base-mediated 
elimination to form an enamine which combined in a [4+2] cycloaddition with a ketene generated in situ 
(Figure 3.9).36  Stereochemistry of the thiazinone directly results from the stereochemistry of the alkaloid 
catalyst; TMS-quinine results in the formation of 29a while TMS-quinidine results in the formation of 
29b.   
 
 
Figure 3.8. Synthesis of Syn-β2,3-Monomers 
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 A major problem involved in the formation of the thiazinone product of this reaction is the β-
branched structure of the isopropyl substituent; there is significant steric crowding resulting from the 
close proximity of the isopropyl and methyl groups in the ring.  The steric crowding caused the 
cyclization reaction to be disfavored while promoting the formation of ketene dimer (Figure 3.10).  
Several combinations of temperature and catalyst loading were tested before arriving at the optimal 
conditions of -78 °C and 40 mol % catalyst loading.  Even with the optimized conditions, overall yield of 
the reaction was consistently low (~15%).  Nevertheless, we were able to isolate sufficient material to 
synthesize peptides and test our hypotheses. 
 
 
 
 
Figure 3.9. Transition State of Thiazinone Formation 
 
 
Figure 3.10. Ketene Dimer Formation 
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 In addition to factoring into low yield, formation of the ketene dimer was a significant problem in 
the purification of the product.  The dimer impurity co-eluted with the thiazinone product during column 
chromatography, even in the cases where the separation was attempted multiple times.  A simple solution 
to remove the ketene dimer was to vacuum pump the product as the ketene dimer is volatile.   Our early 
efforts toward this monomer used a volatile O-ethyl thiocarbamate.  In order to decrease the volatility of 
the product, the O-butyl thiocarbamate functionality was used to increase the molecular weight.  
Increased molecular weight decreased the volatility of the product and therefore allowed for ketene dimer 
to be removed by vacuum.  Even after vacuum, the thiazinone product still contained a minor 
contaminant.  To provide separation from this impurity, 29a and 29b were ring-opened using lithium 
hydroxide to form thiocarbamate protected monomers 30a and 30b which were purified to homogeneity 
and coupled without issue during solid-phase peptide synthesis.45  
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3.1.7. Fmoc-cis-ACPC Monomer Synthesis 
 
 
 
 
 
Fmoc-cis-ACPC monomers 33a and 33b were synthesized by enzymatic resolution of lactam precursors 
31 and 34.  To generate lactam precursor 31, chlorosulfonyl isocyanate was added to a solution of 
cyclopentene in a [2+2] addition reaction.43  Subsequent addition of sodium thiosulfate under basic 
conditions yielded 31 in a reductive hydrolysis reaction.   Lactam 31 was selectively opened using Lipase 
B;37  the resulting amino acid 32 was Fmoc protected to yield 33a.43  Lipase B selectively opens the 
(1R,2S) enantiomer of 31, leaving the (1S,2R) lactam which can be ring opened with hydrochloric acid.  
After several optimization attempts, however, complete enzymatic resolution could not be obtained.  
Thus, amino acid 32 was of high e.e., but the remaining lactam 31 was not sufficiently pure to carry 
forward.  Fmoc-monomer 33b was obtained using a different enzymatic resolution technique.  Lactam 31 
was reacted with paraformaldehyde to produce racemic 34.38  Lipase PS and vinyl butyrate were added to 
 
 
Figure 3.11. Synthesis of Fmoc-cis-ACPC Monomers 
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a solution of 34 and driven to 60% resolution as indicated by NMR.  Lipase PS converts the 
hydroxymethyl group of 34 to a butyl ester (Figure 3.12).  Allowing the reaction to proceed to 60% 
resolution ensured that all of the undesired enantiomer was converted to the ester.  The alcohol and ester 
were then separated using column chromatography to isolate pure 35. 
 
 
 
 
  
 
 Compound 35 was converted to 36 by hydrolysis with aqueous ammonium hydroxide.38  Lactam 
36 was ring-opened with hydrochloric acid to generate amino acid 37 which was directly converted to the 
Fmoc monomer 33b.43 
 
  
 
 
Figure 3.12. Enzymatic Resolution Products Using Lipase PS 
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3.1.8. Fmoc-cis-ACHC Monomer Synthesis 
 
 
 
 
 
Fmoc-cis-ACHC monomers 44a and 44b were synthesized using Lipase PS in a similar route to that used 
for the ACPC monomers.  Chlorosulfonyl isocyanate was added to a solution of cyclopentene, resulting in 
a [2+2] cycloaddition.43  Subsequent treatment with sodium thiosulfate under basic conditions yielded 38 
in a reductive hydrolysis reaction.   
Lactam 38 was reacted with paraformaldehyde to produce racemic 39.38   Lipase PS and vinyl 
butyrate were added to a solution of 39 and driven to 40% resolution as indicated by NMR.  Lipase PS 
converts the hydroxymethyl group of 39 to a butyroyl ester.  Allowing the reaction to proceed to 40% 
resolution ensured that very little of the undesired enantiomer was converted to the ester.  After washing 
the enzyme, purification with column chromatography yielded ester 40. 
 
 
Figure 3.13. Synthesis of Fmoc-cis-ACHC Monomers 
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Lipase PS and vinyl butyrate were added to a solution of 39 and driven to 60% resolution as 
indicated by NMR.  Allowing the reaction to proceed to 60% resolution ensured that all of the undesired 
enantiomer was converted to the ester.  The alcohol and ester were then separated using column 
chromatography to yield N,O-hemiacetal 41. 
Ester 40 and alcohol 41 were converted to 42a and 42b by hydrolysis with aqueous ammonium 
hydroxide.38  The enantiomerically pure lactams were then ring-opened with hydrochloric acid to generate 
acid hydrochlorides 43a and 43b which were converted to Fmoc monomers 44a and 44b using a standard 
protection procedure.43 
 
3.1.9. Peptide Synthesis and NMR Methodology 
 
All peptides were synthesized using standard microwave-assisted Fmoc solid phase synthesis techniques 
and purified by preparative HPLC.  Purity was verified using reverse-phase HPLC and identity of each 
peptide confirmed using MALDI-TOF. 
 Each peptide in aqueous 100 mM deuterated sodium acetate buffer, pH 3.8, was fully assigned 
using TOCSY, NOESY, and COSY 2D NMR.   Spectral assignments were used to check for long-range 
NOE’s, chemical shift deviations, and glycine separation patterns.  3D structures for peptides 
characterized as well-folded by long-range NOE’s were calculated from NOE distance restraints using the 
CNS software package.  
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3.1.10. Peptides Analyzed 
 
We used the protected amino acid monomers described above to generate peptides 3a-18a and 3b-18b.  
As discussed previously, these peptides represent 16 different monomers incorporated at the 3 and 10 
positions of hairpin peptide 2a and unfolded control sequence 2b.  Each of these peptides was analyzed 
using the NMR techniques explained previously and the resulting data were used to generate conclusions 
about the impact of β-residue structure and stereochemistry on the folding of hairpin sequence 2a.  
 
  
2a      H-RWQYV[DPG]KFTVQ-NH2 
2b  H-RWQYV[LPG]KFTVQ-NH2 
3a-18a  H-RWXYV[DPG]KFXVQ-NH2 
3b-18b H-RWXYV[LPG]KFXVQ-NH2 
 
 
 
Figure 3.14. Peptides Studied 
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3.1.11. NMR Analysis 
 
In order to determine the effect of β-residue substitution in this model system, the α-residues found at 
positions 3 and 10 of 2a were replaced with β-residues.  Positions 3 and 10 were chosen so as not to 
disrupt the hydrophobic core of the hairpin.  The mixed α/β-peptides were analyzed by 2D NMR to 
determine the effect of the β-residue substitutions on folded population.  Assuming a two-state 
equilibrium between a single folded and unfolded conformation, folded population, v, can be related to 
the equilibrium constant of folding, K, by the equation in Figure 3.15.46 
 
 
 
𝐾 = 𝑣1 − 𝑣 
 
Figure 3.15. Equilibrium Constant of Folding 
 
 
 
K can in turn be related to ΔG by the equation in Figure 3.16: 
 
 
 
∆𝐺° = −𝑅𝑇𝑙𝑛(𝐾) 
 
Figure 3.16. Gibbs Free Energy of Folding 
 
 
 
The folded population of 2a is 61% at 275 K,29 proportionate to a ΔG° value of -0.2 kcal/mol, so even a 
minor change to the stability of the folded structure should result in a significant shift in folded 
population.   
One effective measure of β-hairpin folded population is the comparison of chemical shifts of the 
two diastereotopic protons found in the glycine residue.47,48  In a random coil peptide, the chemical shifts 
of the two glycine protons are identical due to a large ensemble of conformations.  As the population of a 
single folded state increases, the protons become locked in specific conformations more frequently and 
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the diastereotopic nature of the protons becomes more apparent.  The chemical shifts of the glycine 
protons will split and give a larger numerical difference if a peptide is better folded. 
Comparison of chemical shift deviation between a folded and unfolded peptide can also be used 
to determine the folded population.28,49   β-Hairpin peptides rapidly equilibrate between the hairpin folded 
state and a random coil unfolded state.50  Because these two states are in rapid exchange, the measured 
chemical shifts will show a weighted average of the chemical shifts of each state; a partially folded 
peptide will give chemical shift values between the values of a fully folded and fully unfolded peptide.  
Without a fully folded control, as in the case of this study, the population cannot be quantitatively 
measured, but comparing the test peptide data to that of an unfolded control gives qualitative evidence for 
folding.  Peptide 2a can be made into an unfolded control simply by replacing the D-Pro residue with an 
L-Pro residue.  When an L-Pro residue replaces the D-Pro residue in the D-Pro-Gly turn of a β-sheet, as in 
the case of peptide 2b, it causes complete unfolding by disrupting the turn.29 
2b H-RWQYV[LPG]KFTVQ-NH2 
 Folded structure can be determined using qualitative NOE analysis.49,51  If a peptide has a large 
folded population, long-range NOE’s between the two strands of the hairpin should be apparent.  Well-
folded peptides should exhibit NOE’s along the entire length of the hairpin while poorly-folded peptides 
should exhibit NOE’s only along the turn region.  In addition to qualitative analysis, NOE’s can also be 
used quantitatively to generate high resolution structures of the folded state of a peptide.  Using the 
measured intensity of NOE cross-peaks, distance restraints between residues can be established.  These 
distance restraints can then be used to generate high resolution structures of the peptide. 
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3.1.12. Glycine Separation Analysis 
 
The proton resonances of peptides 2a-18a were fully assigned using their respective TOCSY, NOESY, 
and COSY spectra.  From these data, the chemical shifts of the Hα protons of the glycine-7 residue were 
measured.  The difference between the two chemical shifts was then calculated for each peptide and 
plotted (Figure 3.17).  
 
 
 
 
 
 
The glycine separation analysis shows four peptides with significant deviations in Hα separation; 
model peptide (2a), the two peptides incorporating syn-β2,3-residues (9a, 10a), and one peptide 
incorporating a cis-ACHC residue (17a).  This observation suggests that peptides 9a, 10a, and 17a may 
have folded populations similar to peptide 2a.  Of note, the values for peptides 9a and 10a are at least 
20% higher than the value for peptide 2a, suggesting these peptides may actually be better folded than the 
control peptide.  Without a fully folded control, however, no actual folded population could be calculated 
for these peptides. 
 
Figure 3.17. Glycine-7 Separation Values 
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3.1.13. Chemical Shift Deviation Analysis  
 
Recall that substitution of D-Pro with an L-Pro residue generates an unfolded control.  The chemical shift 
values for backbone N-H protons (HN) and C-H protons (Hα/β) were compared within each D-Pro (2a-18a) 
and L-Pro peptide pair (2b-18b).  The values of the HN and Hα/β chemical shifts of each residue, excluding 
the N-terminal residue, R1, and the two turn residues, P6 and G7, were measured.  The differences in 
values between the test peptides and unfolded controls were then calculated and their absolute values 
summed and tabulated. (Figure 3.18).   
 
 
 
 
  
 
 
 The chemical environment of a proton in a random coil is markedly different than the 
environment in a folded sheet.  A large chemical shift deviation from random coil values is indicative of a 
well-folded secondary structure while a smaller chemical shift deviation is indicative of a less-folded 
structure.  Analysis of both sets of chemical shift deviation values suggests that peptides 9a and 10a, 
which contain the syn-β2,3-monomers, are closest in chemical shift deviation to the model peptide, 2a.  
Peptides 9a and 10a show larger chemical shift deviation than the other β-substituted peptides for both 
 
Figure 3.18. HN (A) and Hα/β (B) Chemical Shift Deviation Values 
A B 
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the Hα/β and HN data.  The chemical shift deviation data supports the data given by the glycine separation 
analysis; peptides 9a and 10a have a higher folded population than the other peptides studied. 
 
3.1.14. Backbone NOE Analysis 
 
Another means of assessing folded structure involves backbone NOE analysis.49,51  A β-sheet with a large 
folded population will show long-range NOE’s all along the length of the backbone.  Peptides without a 
large folded population will tend to show only short-range NOE’s such as those found between adjacent 
residues.  
 Peptides 2a-18a were analyzed for long-range NOE’s.  Peptides 6a, 13a, and 16a-18a showed no 
NOE’s indicative of folding.  Peptides 4a, 5a, 7a, 8a, 11a, 12a, 14a, and 15a showed NOE’s near the turn 
region but showed no correlation past the unnatural residues.  Peptides 2a, 3a, 9a, and 10a showed 
correlations throughout the entire length of the chain (Figure 3.19).  These data suggest that only peptides 
2a, 3a, 9a, and 10a are folded relatively well into hairpin conformations.  For other, less-folded peptides, 
insertion of the unnatural β-residue leads to fraying past the unnatural residue, disrupting any long-range 
NOE contacts.  Peptides 2a, 3a, 9a, and 10a are most interesting for future study as they provide a well-
folded hairpin structure might be effective mimics of β-sheet structures found in natural proteins. 
While peptides 3a, 9a, and 10a do show folding, it is interesting to note that the insertion of the 
unnatural residues causes inversion of the side-chains and H-bond pattern past the unnatural residue.  
Unlike the conformation found in natural α-peptides (Figure 3.20A), insertion of the additional carbon 
atom found in the β-monomers causes side-chain inversion (Figure 3.20C).  None of the unnatural 
residues we examined provided conformational restraints that would force the retention of the natural 
side-chain display (Figure 3.20B). 
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*Ambiguous assignments shown as dotted lines. 
 
Figure 3.19. Long-Range Backbone NOE’s* Found in Peptides 2a-5a, 7a-12a, 14a, and 15a 
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3.1.15. High-Resolution 3D Structures 
 
Based on the conclusions drawn from the NMR data, high-resolution 3D structures of model α-peptide 2a 
and test α/β-peptides 3a, 9a, and 10a were constructed by simulated annealing with NMR-derived 
distance restraints.  The 20 lowest energy structures of peptides 2a, 3a, 9a, and 10a show excellent 
agreement (Figure 3.21A), indicating a consistent folded structure.  The minimum energy average 
structure for each peptide shows a β-hairpin fold (Figure 3.21B). 
 
 
Figure 3.20. Side-Chain Display Orientations Found in Peptides Studied 
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 These data highlight several important details about the folded structures of the peptides studied.  
As expected from the qualitative NOE analysis, peptides 3a, 9a, and 10a all show side-chain inversion 
past the unnatural residue (Figure 3.22).   
 
 
 
 
 
 
 
Figure 3.21. NMR 3D Structures of Peptides 2a, 3a, 9a, and 10a 
 
 
Figure 3.22. Overlay of Peptide 2a (Yellow) and Peptide 9a (Purple) 
A 
B 
38 
 
 Additionally, comparing the structures unnatural peptides to peptide 2a allows us to ask which is 
best at mimicking a natural sheet.  The overlay of peptides 2a with peptide 3a (Figure 3.23A) shows that 
peptide 3a adopts a more twisted conformation than the standard staggered conformation of a β-sheet.  
Overlays of 2a with 9a and 2a with 10a show a more natural sheet conformation, although peptides 9a 
and 10a both have kinks in the chain near the unnatural residues (Figure 3.23B).  Another important note 
is that peptide 9a has a more vertical display of the side-chain found in the unnatural residue as compared 
to peptide 10a, where the side-chain has a more horizontal display (Figure 3.23C).  The vertical side-
chain display of peptide 9a more closely matches the display of side-chains in the natural peptide, 2a. 
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*Some side chains have been removed for clarity.  β-residue carbons are colored cyan. 
 
Figure 3.23. Overlays* of Peptides 2a, 3a, 9a, and 10a 
A B 
C 
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3.2. EXPERIMENTAL 
 
3.2.1. General Information 
 
Optical rotations were measured on a Perkin-Elmer 241 digital polarimeter with a sodium lamp at 
ambient temperature. NMR spectra of synthetic compounds were recorded on a Bruker Avance-300 or 
Bruker Avance-400 spectrometer. Fmoc-L-β3-homovaline and Fmoc-D-β3-homovaline were purchased 
from PepTech. 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate 
(HCTU), NovaPEG Rink Amide Resin, 9-Fluorenylmethyl succinimidyl carbonate, and Fmoc-protected 
α-amino acids were purchased from Novabiochem. Solvents and all other reagents were purchased from 
Aldrich, Baker, EMD, Fisher, or TCI and used as received without further purification unless otherwise 
stated. Anhydrous ether was distilled over solid sodium and benzophenone. Anhydrous dichloromethane 
was distilled over solid calcium hydride. Propionyl chloride was distilled prior to use. Lithium iodide was 
weighed out in a glove bag under nitrogen atmosphere and stored under nitrogen until use. Flash 
chromatography was performed using Silicycle SiliaFlash P60 (230-400 mesh) silica gel. O-
trimethylsilylquinidine (TMS-quinidine) and O-trimethylsilylquinine (TMS-quinine) were synthesized 
using a published procedure.52 Both trans-2-amino-1-cylcopentanecarboxylic acid (ACPC) monomers40 
and trans-2-amino-1-cyclohexanecarboxylic acid (ACHC) monomers41 were synthesized using published 
procedures.  Spectral data for unprecedented compounds can be found in Appendix A.   
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3.2.2. Fmoc-β2-Monomer Synthesis  
 
  
Aldehydes 21a and 21b were prepared by a published procedure.32,33 
General Procedure A.  Synthesis of Fmoc-β2-Monomers 23a and 23b: 33 To a solution of benzylated 
aldehyde (1 equiv) in 5 mL methanol was added Pd/C (20 wt%).  This solution placed on a Parr apparatus 
at 40 psi and allowed to shake overnight. The solution was then filtered through celite and concentrated.  
The isolated material was then dissolved in 5 mL methanol.  To this solution was added ammonium 
formate (10 equiv) and Pd/C (60 wt%) and the solution refluxed 5 h.  The solution was then filtered 
through celite and concentrated to yield the crude debenzylated amine.  The crude amine was dissolved in 
5 mL dichloromethane.  To this solution was added DIEA and 9-fluorenylmethyl succinimidyl carbonate 
(Fmoc-OSu).  The reaction mixture was stirred 1 h, then diluted with 100 mL ethyl acetate, washed with 
aqueous 5% sodium bisulfate, aqeuous 5% sodium bicarbonate, and brine.  The organic layer was then 
dried with magnesium sulfate and concentrated.  The residue was partially purified using column 
 
 
Figure 3.24. Fmoc-β2-Monomer Synthesis 
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chromatography (33% ethyl acetate in hexanes) to afford the product and residual Fmoc-OSu.  Jones 
reagent was prepared by dissolving sodium dichromate (2.98 g, 10 mmol, 1 equiv) in 10 mL water. 
Concentrated sulfuric acid (2.22 mL, 40 mmol, 4 equiv) was added slowly with stirring. The solution was 
then diluted to 0.5 M with 8 mL water.  Jones reagent (2 equiv) was added slowly to a solution of the 
Fmoc-amino alcohol (1 equiv) in 10 mL acetone at 0 °C.  The reaction mixture was allowed to warm to 
room temperature and stirred for 2 h after which 2 mL of isopropanol was added and the reaction stirred 
for an additional 2 h.  The solution was then diluted in 150 mL ethyl acetate and washed with 50 mL 
aqueous 5% sodium bisulfate.  The organic layer was dried with magnesium sulfate and concentrated.   
The residue was purified using column chromatography to afford the product. 
(S)-2-Fmoc-amino-3-methylbutanoic acid (23a): General procedure A was 
employed using 485 mg compound 21a (1.56 mmol) with 100 mg Pd/C.  The 
mixture was resubjected using 983 mg ammonium formate (15.6 mmol) and 300 mg 
Pd/C.  General procedure A was again employed using 271 µL DIEA (1.56 mmol) and 526 mg Fmoc-
OSu (1.56 mmol). The crude Fmoc-amino alcohol was oxidized with 4.0 mL 0.5 M Jones reagent 
solution as described.  Column chromatography (33% ethyl acetate in hexanes) afforded the product as a 
white solid (160 mg, 0.453 mmol, 29.0% yield over three steps). Spectral data matched previously 
published results.42 [α]D = +3.3 (c = 1.0, CHCl3). 
(R)-2-Fmoc-amino-3-methylbutanoic acid (23b): General procedure A was 
employed using 320 mg compound 21b (1.03 mmol) with 66 mg Pd/C.  The mixture 
was resubjected using 650 mg ammonium formate (10.3 mmol) and 198 mg Pd/C.  
General procedure A was again employed using 179 µL DIEA (1.03 mmol) and 347 mg Fmoc-OSu (1.03 
mmol). The crude Fmoc-amino alcohol was oxidized with 2.6 mL 0.5 M Jones reagent solution as 
described.  Column chromatography (25% → 33% ethyl acetate in hexanes) afforded the product as a 
white solid (172 mg, 0.487 mmol, 47.3% yield over three steps). Spectral data matched previously 
published results.42 [α]D = −3.1 (c = 1.0, CHCl3), [α]D = −17 (c = 1.0, MeOH). 
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3.2.3. Fmoc-anti-β2,3-Monomer Synthesis  
 
 
 
 
General Procedure B.  Synthesis of Lactones 24a and 24b:34  To a solution on lithium perchlorate 
(2.12 g, 19.9 mmol, 2 equiv) in 10 mL anhydrous ether was added O-trimethylsilyl-quinine or O-
trimethylsilyl-quinidine (400 mg, 1 mmol, 0.1 equiv) and 20 mL anhydrous dichloromethane.  The 
reaction mixture was cooled to  −40 °C. DIEA (4.36 mL, 25.0 mmol, 2.5 equiv) and isobutyraldehyde 
(0.92 mL, 10 mmol, 1 equiv) were then added to the solution. Propionyl chloride (1.74 mL, 19.9 mmol, 2 
equiv) was dissolved in 5 mL anhydrous dichloromethane. The solution of propionyl chloride was then 
added dropwise to the reaction over the course of 3 h. Upon completion of the addition, the reaction was 
allowed to stir at −40 °C for 16 h. After this time, 20 mL of ether was added to the solution. The resulting 
mixture was filtered through a silica plug and washed with ether. The solution was concentrated at a light 
vacuum (as the product is volatile).  Column chromatography (10% ether in pentane) afforded the 
product.   
 
 
Figure 3.25. Fmoc-anti-β2,3-Monomer Synthesis 
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(3R,4S)-4-isopropyl-3-methyloxetan-2-one (24a): General procedure B was employed 
using O-trimethylsilyl-quinine to afford 3.61 mmol of product (36.1% yield) which was used 
directly in the next step. 1H NMR (300 MHz, CDCl3) δ 4.12 (dd, J = 6.07, 10.63 Hz, 1 H), 
3.72 (m, 1 H), 2.00 (m, 1 H), 1.34 (d, J = 7.59 Hz, 3 H), 1.08 (d, J = 6.45 Hz, 3 H), 0.92 (d, J = 6.83 Hz, 3 
H).  
(3S,4R)-4-isopropyl-3-methyloxetan-2-one (24b):  General procedure B was employed 
using O-trimethylsilyl-quinidine to afford 4.56 mmol of product (45.6% yield) which was 
used directly in the next step.  1H NMR (300 MHz, CDCl3) δ 4.11 (dd, J = 6.07, 10.63 Hz, 1 
H), 3.73 (m, 1 H), 2.00 (m, 1 H), 1.34 (d, J = 7.97 Hz, 3 H), 1.08 (d, J = 6.45 Hz, 3 H), 0.93 (J = 6.83 Hz, 
3 H). 
General Procedure C.  Synthesis of Azido Acids 25a and 25b: 35  To a solution of sodium azide (2 
equiv) in DMSO was added lactone (1 equiv).  The reaction mixture was stirred at 50 °C for 48 h. The 
reaction vessel was then cooled to room temperature and 8 mL of saturated aqueous sodium bicarbonate 
was added. Water was added until the salts in the solution dissolved and the aqueous layer was washed 
twice with ethyl acetate. 1 M hydrochloric acid was used to acidify the aqueous layer which was 
subsequently extracted three times with ethyl acetate. Caution should be observed here as addition of acid 
to the aqueous layer could result in the formation of toxic HN3 gas. The addition of acid was done in a 
hood and the resulting acidic waste neutralized with aqueous sodium hydroxide solution. The organic 
layers were combined and washed twice with water and twice with brine. The organic layer was dried 
over sodium sulfate, concentrated, and dried under vacuum. 
(2R,3R)-3-azido-2,4-dimethylpentanoic acid (25a):  General procedure C was 
employed using 468 mg sodium azide (7.20 mmol) in 12 mL anhydrous DMSO and 24a 
(3.61 mmol).  Drying under vacuum afforded the product as a colorless oil (466 mg, 2.72 
mmol, 75.3% yield) that was used without further purification. [α]D = −12 (c = 1.0, CHCl3). 1H NMR 
(400 MHz, CDCl3) δ 3.43(dd, J = 4.77, 4.27, 9.03 Hz, 1 H), 2.66 (m, 1 H), 2.01 (m, 1 H), 1.24 (d, J = 
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7.03 Hz, 3 H), 1.09 (d, J = 6.78 Hz, 3 H), 0.91 (d, J = 6.78 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 
179.9, 70.6, 42.4, 29.6, 20.6, 15.8, 14.6. HRMS m/z calcd for [C7H12N3O2] 170.0930; found 170.0938. 
(2S,3S)-3-azido-2,4-dimethylpentanoic acid (25b):  General procedure C was 
employed using 595 mg sodium azide (9.16 mmol) in 15.2 mL anhydrous DMSO and 
24b (4.58 mmol).  Drying under vacuum afforded the product as a colorless oil (523 mg, 
3.06 mmol, 66.8% yield). [α]D = +11 (c = 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 3.43(dd, J = 4.52, 
4.27, 9.03 Hz, 1 H), 2.66 (m, 1 H), 2.01 (m, 1 H), 1.24 (d, J = 7.28 Hz, 3 H), 1.09 (d, J = 6.78 Hz, 3 H), 
0.91 (d, J = 6.78 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 180.0, 70.6, 42.4, 29.6, 20.6, 15.8, 14.6. 
HRMS m/z calcd for [C7H13N3O2] 177.1008; found 171.1003. 
General Procedure D.  Reduction of Azido Acids: 35,43  Azido acid (1 equiv) was dissolved in methanol.  
The reaction vessel was flushed with nitrogen and Pd(OH)2/C, 20 wt% (25% w/w) was added. The vessel 
was fitted with a hydrogen-filled balloon and stirred for 24 h.  The solution was then filtered through 
celite, washed with methanol, and concentrated to yield crude amino acid.   
General Procedure E. Standard Fmoc Protection:43 To a solution of amine  (1 equiv) in water in a 
screw-cap vial was added potassium bicarbonate (1 or 2 equiv), 9-fluorenylmethyl succinimidyl carbonate 
(Fmoc-OSu) (1 equiv), and acetone. The vial was sealed and allowed to stir for 2 days. The reaction was 
then acidified with 2 mL 1 M hydrochloric acid and water was added to dissolve salts. The reaction 
mixture was extracted three times with ethyl acetate. The organic layers were combined, dried with 
magnesium sulfate, and concentrated.  The concentrate was purified using column chromatography and 
dried under vacuum to afford the product. 
(2R,3R)-3-Fmoc-amino-2,4-dimethylpentanoic acid (26a):  General procedure D 
was employed using 233 mg compound 25a (1.36 mmol), 58 mL methanol, and 58 
mg Pd(OH)2/C, 20 wt%.  General procedure E was then employed using the amino 
acid (1.36 mmol), 4 mL water, 136 mg sodium bicarbonate (1.36 mmol), 456 mg Fmoc-OSu (1.36 
mmol), and 4 mL acetone.  Column chromatography (10% ethyl acetate in hexanes → 33% ethyl acetate 
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in hexanes with 1% acetic acid) afforded the product as a white foam (207 mg, 0.563 mmol, 41.4% yield 
over 2 steps). [α]D = +18 (c = 1.0, CHCl3). This compound exists as a series of conformers in slow 
exchange on the NMR timescale. 1H NMR of main conformer (400 MHz, DMSO-d6) δ 12.18 (s, 1 H), 
7.89 (d, J = 6.04 Hz, 2 H), 7.71 (t, J = 6.78 Hz, 2 H), 7.41 (t, J = 7.20 Hz, 2 H), 7.32 (qd, J = 6.78, 0.64 
Hz, 2 H), 7.02 (d, J = 10.06 Hz, 1 H), 4.24 (m, 3 H), 3.55 (qd, J = 8.68, 1.87 Hz, 1 H), 2.54 (m, 1 H), 1.81 
(m, 1 H), 1.04 (d, J = 6.36 Hz, 3 H), 0.84 (d, J = 6.83 Hz, 3 H), 0.80 (d, J = 6.59 Hz, 3 H); 13C NMR (100 
MHz, CDCl3) δ 178.18, 156.07, 143.96, 143.79, 140.69, 127.59, 127.06, 127.02, 125.35, 125.26, 120.08, 
65.30, 57.75, 46.78, 41.59, 28.96, 20.00, 17.27, 14.26. HRMS m/z calcd for [C22H24NO4] 366.1739; found 
366.1705. 
(2S,3S)-3-Fmoc-amino-2,4-dimethylpentanoic acid (26a):  General procedure D 
was employed using 125 mg compound 25a (0.73 mmol), 31 mL methanol, and 31 
mg Pd(OH)2/C, 20 wt%.  General procedure E was then employed using the amino 
acid (0.73 mmol), 0.9 mL water, 100 mg sodium bicarbonate (0.73 mmol), 245 mg Fmoc-OSu (0.73 
mmol), and 0.9 mL acetone.  Column chromatography (10% ethyl acetate in hexanes → 33% ethyl 
acetate in hexanes with 1% acetic acid) afforded a mixture of 9-fluorenylmethanol and the product as a 
white foam (85 mg, 0.23 mmol, 32% yield over 2 steps).  An analytically pure sample was obtained by 
repeating the protocol above and using 1 equivalent of potassium bicarbonate. Pure product fractions 
were obtained using column chromatography (20% ethyl acetate in hexanes with 1% acetic acid). These 
fractions were solvent exchanged with n-heptane and CHCl3 and were then dried under vacuum to yield a 
white foam. [α]D = −23 (c = 1.0, CHCl3. This compound exists as a series of conformers in slow 
exchange on the NMR timescale. 1H NMR of main conformer (400 MHz, DMSO-d6) δ 12.18 (s, 1 H), 
7.89(d, J = 7.53 Hz, 2 H), 7.71 (t, J = 7.78 Hz, 2 H), 7.41 (t, J = 7.53 Hz, 2 H), 7.32 (qd, J = 7.52, 0.97 
Hz, 2 H), 7.03 (d, J = 9.79 Hz, 1 H), 4.24 (m, 3 H), 3.55 (qd, J = 7.03, 2.76 Hz, 1 H), 2.54 (m, 1 H), 1.81 
(m, 1 H), 1.04 (d, J = 7.03 Hz, 3 H), 0.84 (d, J = 6.78 Hz, 3 H), 0.80 (d, J = 6.78 Hz, 3 H); 13C NMR (100 
MHz, CDCl3) δ 176.65, 156.55, 144.45, 144.28, 141.17, 128.08, 127.55, 127.51, 125.83, 125.74, 120.57, 
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65.78, 58.24, 47.26, 42.07, 29.45, 20.49, 17.77, 14.76. HRMS m/z calcd for [C22H24NO4] 366.1705; found 
366.1718. 
 
3.2.4. Syn-β2,3-Monomer Synthesis 
 
O-butyl carbamothioate (27): Compound 27 was synthesized using a modification of a 
previously published procedure.44 Potassium butyl xanthate (27.1 g, 144 mmol, 1 equiv) 
was dissolved in 130 mL water. Chloroacetic acid (13.6 g, 144 mmol, 1 equiv) was dissolved in 130 mL 
water in a separate flask and cooled to 0 °C after which sodium hydroxide (5.76 g, 144 mmol, 1 equiv) 
was added. The chloroacetic acid solution was added to the xanthate solution and stirred overnight. After 
this time, 28% aqueous ammonium hydroxide (11.67 mL, 173 mmol, 1.2 equiv) was added and the 
reaction was stirred overnight. The reaction was then extracted five times with ether. The organics were 
combined, dried with magnesium sulfate, and concentrated to yield a colorless oil (17.129 g, 129 mmol, 
89.6% yield). 1H NMR (400 MHz, CDCl3) δ 7.08 (s, 1 H), 6.27 (s, 1 H), 4.34 (t, J = 6.78 Hz, 2 H), 1.62 
 
 
Figure 3.26. Syn-β2,3-Monomer Synthesis 
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(m, 2 H), 1.33 (m, 2 H), 0.88 (t, J = 7.53 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 192.69, 71.61, 30.53, 
18.95, 13.69.  HRMS m/z calcd for [C10H23N2O2] (2M+H)+ 267.1201; found 267.1225. 
Sulfone (28): Compound 28 was synthesized using a modification of a published 
procedure.36 Carbamothioate 27 (7.0 g, 53 mmol, 1 equiv) was dissolved in 60 mL water. 
Sodium para-toluenesulfinate (12.25 g, 63.1 mmol, 1.2 equiv), isobutyraldehyde (5.76 
mL, 63.1 mmol, 1.2 equiv), and formic acid (13.7 mL, 362 mmol, 6.9 equiv) were added 
and the reaction was allowed to stir for 2 days. The solution was then extracted with 150 
mL dichloromethane. The organic layer was washed twice with 100 mL water and once with 100 mL 
brine, dried over magnesium sulfate, and concentrated. After scratching the container with a glass pipette 
and drying under vacuum, the product crystallized as a white solid (16.173 g, 47.1 mmol, 90% yield). 
This compound exists as a series of conformers in slow exchange on the NMR time scale; NMR spectra 
are attached. HRMS m/z calcd for [C16H25NO3NaS2] 366.1198; found 366.1192. 
General Procedure F.  Synthesis of Thiazinones 29a and 29b:36  To a solution of sulfone 28 (1 equiv) 
in anhydrous dichloromethane was added O-trimethylsilyl-quinine or O-trimethylsilyl-quinidine (0.4 
equiv).  The reaction mixture was cooled to −78 °C and DIEA (3.6 equiv) was added.  Lithium iodide 
(0.63 equiv) was dissolved in anhydrous ether and added to the reaction solution. Propionyl chloride (2.5 
equiv) was dissolved in anhydrous dichloromethane to create a 4 M solution that was divided into 5 equal 
portions. One portion of this solution was added dropwise to the reaction over 20 minutes. After this 
addition, the reaction was allowed to stir for 1 hour before another aliquot of lithium iodide (0.63 equiv) 
in ether was added. Another portion of the acid chloride solution was added over 20 minutes and the 
reaction was allowed to stir for 1 hour. This sequence (addition of lithium iodide followed by dropwise 
addition of acid chloride) was repeated three times and the reaction was allowed to stand at −78 °C for 16 
h. After this time, 0.5 mL acetic acid in 4.5 mL anhydrous ether was added.  The solution was 
immediately washed three times with saturated aqueous ammonium chloride solution. The aqueous 
washes were combined and extracted once with ether. The ether and organic layers were combined and 
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washed three times with brine. The organic layer was then run through a silica plug, eluting with ether. 
The solvent was concentrated and purified using column chromatography.   
Thiazinone (29a):  General procedure F was employed using 1.02 g compound 28 (2.96 
mmol), 470 mg O-trimethylsilylquinine (1.18 mmol), 26 mL anhydrous dichloromethane, 
1.88 mL DIEA (10.8 mmol) five portions of 250 mg lithium iodide (1.87 mmol) in 3.6 
mL anhydrous ether, and 0.65 mL propionyl chloride (7.5 mmol).  The crude reaction 
mixture was purified using column chromatography (0.5% ethyl ether in pentane) to afford a mixture of 
the product and ketene dimer. The impure mixture was dried under vacuum to eliminate any residual 
ketene dimer, affording the product as a yellow oil (67 mg, 0.28 mmol) that was used directly in the next 
step. 1H NMR (300 MHz, CDCl3) δ 4.29 (t, J = 6.8 Hz, 2 H), 3.03 (dd, J = 3.02, 9.63 Hz, 1 H), 2.77 (qd, J 
= 2.83, 7.18 Hz, 1H), 1.92 (m, 1 H), 1.70 (m, 2 H), 1.43 (m, 2 H), 1.11 (d, J = 6.61 Hz, 3 H), 1.02 (d, J = 
7.18 Hz), 0.96 (t, J = 7.18 Hz, 3 3 H), 0.95 (d, J = 6.61 Hz, 3 H). 
Thiazinone (29b):  General procedure F was employed using 1.13 g compound 28 (3.28 
mmol), 520 mg O-trimethylsilylquinidine (1.31 mmol), 28 mL anhydrous 
dichloromethane, 2.08 mL DIEA (11.9 mmol) five portions of 250 mg lithium iodide 
(1.87 mmol) in 3.6 mL anhydrous ether, and 0.72 mL propionyl chloride (8.3 mmol).  The 
crude reaction mixture was purified using column chromatography (0.5% ethyl ether in pentane) to afford 
a mixture of the product and ketene dimer. The impure mixture was dried under vacuum to eliminate any 
residual ketene dimer, affording the product as a yellow oil (160 mg, 0.66 mmol) that was used directly. 
1H NMR (300 MHz, CDCl3) δ 4.29 (t, J = 6.61 Hz, 2 H), 3.03 (dd, J = 3.02, 9.63 Hz, 1 H), 2.77 (qd, J = 
2.83, 7.18 Hz, 1H), 1.92 (m, 1 H), 1.70 (m, 2 H), 1.43 (m, 2 H), 1.11 (d, J = 6.61 Hz, 3 H), 1.02 (d, J = 
7.18 Hz), 0.96 (t, J = 7.18 Hz, 3 3 H), 0.95 (d, J = 6.61 Hz, 3 H). 
General Procedure G.  Thiocarbamates 30a and 30b: 45  To a solution of thiazinone (1 equiv) in THF 
was added a solution of lithium hydroxide (3 equiv) in water.  The reaction vessel was stirred overnight 
and then acidified to pH 2 with 1 M hydrochloric acid and extracted three times with dichloromethane. 
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The organics were combined and washed twice with brine, dried over magnesium sulfate, and 
concentrated. The concentrate was purified using column chromatography (20% ethyl acetate in hexanes 
→ 50% ethyl acetate in hexanes) to afford the product.   
Thiocarbamate (30a):  General procedure G was employed using 67 mg 
thiazinone 29a (0.28 mmol), 6.4 mL THF, 19 mg lithium hydroxide (0.82 mmol) 
and 3.2 mL water to afford the product as yellow crystals (58 mg, 0.22 mmol, 
7.5% over two steps). [α]D = +20 (c = 1.0, CHCl3). This compound exists as a series of conformers in 
slow exchange on the NMR timescale; NMR spectra are attached. HRMS m/z calcd for [C12H22NO3S] 
260.1320; found 260.1340. 
Thiocarbamate (30b):  General procedure G was employed using 160 mg 
thiazinone 29b (0.66 mmol), 15.6 mL THF, 46 mg lithium hydroxide (2.0 mmol) 
and 7.66 mL water to afford the product as yellow crystals (144 mg, 0.551 mmol, 
17% over two steps).  [α]D = −17 (c = 1.0, CHCl3). This compound exists as a series of conformers in 
slow exchange on the NMR timescale; NMR spectra are attached. HRMS m/z calcd for [C12H22NO3S] 
260.1320; found 260.1328. 
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3.2.5. Fmoc-cis-ACPC Monomer Synthesis 
 
 
 
N,O-acetal 34, lactam 36,  amino acid 37 were synthesized using published procedures.38,39 
Racemic cis-azabicyclo[3.2.0]heptan-7-one (31):  Lactam 31 was synthesized using a 
modification of a published procedure.43 Cyclopentene (4.5 mL, 51 mmol, 1 equiv) was 
dissolved in 23 mL anhydrous dichloromethane and cooled to 0 °C under nitrogen. 
Chlorosulfonyl isocyanate (4.3 mL, 49 mmol, 1 equiv) was dissolved in 7 mL anhydrous dichloromethane 
and was added dropwise to the cyclopentene solution with stirring over 30 minutes. The reaction was then 
heated to 40 °C and stirred for 20 h. The resulting solution was cooled to 0 °C and quenched with 
dropwise addition of water until bubbling ceased. Anhydrous sodium sulfite (15.8 g, 125 mmol, 2.5 
equiv) and sodium biphosphate heptahydrate (35.1 g, 125 mmol, 2.5 equiv) were dissolved in 240 mL 
 
 
Figure 3.27. Fmoc-cis-ACPC Monomer Synthesis 
52 
 
water. This solution along with 120 mL chloroform was combined with the reaction solution and stirred 
for 36 h. The organic layer was collected and the aqueous layer was extracted with ethyl acetate. The 
organic layers were combined, dried with magnesium sulfate, and concentrated. The resulting solid was 
dissolved in ethyl acetate and recrystallized from pentane to yield white crystals (3.232 g, 29.1 mmol, 
58% yield). NMR spectra matched previously published results.43 
(1R,2S)-2-aminocyclopentanecarboxylic acid (32): Amino acid 32 was synthesized 
using a modification of a published procedure.37 Lactam 31 (1.006 g, 9.05 mmol, 1 equiv) 
was dissolved in 180 mL diisopropyl ether. Lipase B from Candida antarctica 
immobilized on Immobead 150 (9.005 g, 50 mg/mL) and water (0.162 mL, 8.99 mmol, 1 equiv) were 
added to the solution which was stirred under nitrogen at 60 °C for 10 days. After this time, the enzyme 
slurry was filtered off and rinsed with diisopropyl ether. The enzyme was washed with water. The water 
layer was concentrated under vacuum and the resulting solid was dissolved in water and recrystallized 
using acetone. The resulting white solid was filtered off and dried afford the product amino acid (243 mg, 
1.88 mmol, 20.8% yield). NMR spectra matched previously published results.37 
(1R,2S)-2-Fmoc-aminocyclopentanecarboxylic acid (33a): General procedure E 
was employed using 94 mg amino acid 32 (0.73 mmol), 0.485 mL water, 148 mg 
potassium bicarbonate (1.46 mmol) and 245 mg Fmoc-OSu (0.727 mmol).  Column 
chromatography (20% ethyl acetate in hexanes → 50% ethyl acetate in hexanes) afforded the product as a 
white foam (139 mg, 0.396 mmol, 54% yield). [α]D = −29 (c = 0.50, CHCl3). NMR spectra matched 
previously published results.43 HRMS m/z calcd for [C21H21NO4Na] 374.1368; found 374.1366. 
Standard Procedure H: Enzymatic Resolution Using Lipase PS: 38  Amano Lipase PS from 
Burkholderia cepacia (2.0 g) and sucrose (1.2 g) were dissolved in 200 mL 20 mM Tris, pH 7.8. Celite 
(6.8 g) was added and the solution was concentrated to dryness to yield 20% w/w lipase on celite.   The 
N,O-acetal (1 eq) was dissolved in anhydrous acetone (dried for 24 h over sodium sulfate). Vinyl butyrate 
(2 eq) and Lipase PS (1.89 g, 20% w/w on celite) were added to the solution which was allowed to stir 
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until the desired resolution was obtained.   The enzyme was filtered from the solution and washed with 
acetone which was then concentrated.  The concentrate was purified using column chromatography and 
dried under vacuum to afford the desired product.   
(1S,5R)-6-(hydroxymethyl)-6-azabicyclo[3.2.0]heptan-7-one (35): General procedure H was 
employed using 533 mg acetal 34 (3.78 mmol), 38.3 mL acetone, 0.96 mL vinyl butyrate (7.6 
mmol), and 1.89 g Lipase PS.  The reaction was stirred for 36 h when NMR spectroscopy 
indicated 60% conversion.  Column chromatography (50% ethyl acetate in hexanes → 75% 
ethyl acetate in hexanes) afforded the unreacted starting material as a colorless oil (143 mg, 1.01 mmol, 
27% yield). NMR spectra matched previously published results.38 [α]D = −35 (c = 1.0, CHCl3); [α]D, lit = 
−32.4 (c = 1, CHCl3).38  
(1S,2R)-2-Fmoc-aminocyclopentanecarboxylic acid (33b): General procedure E 
was employed using 150 mg acid hydrochloride 37 (0.906 mmol), 1.10 mL water, 
182 mg potassium bicarbonate (1.82 mmol) and 308 mg Fmoc-OSu (0.913 mmol).  
Column chromatography (20% ethyl acetate in hexanes → 50% ethyl acetate in hexanes) afforded the 
product as a white foam (243 mg, 0.692 mmol, 76.3% yield) after column chromatography (20% ethyl 
acetate in hexanes → 50% ethyl acetate in hexanes). [α]D = +29 (c = 0.50, CHCl3). NMR spectra matched 
previously published results.43 HRMS m/z calcd for [C21H21NO4Na] 374.1368; found 374.1352. 
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3.2.6. Fmoc-cis-ACHC Monomer Synthesis 
 
 
 
N,O-acetal 39, amino acid 43a, amino acid 43b were synthesized using published procedures.39 
Racemic cis-7-azabicyclo[4.2.0]octan-8-one (38): Lactam 38 was synthesized using a 
modification of a published procedure.43 Cyclohexene (10.1 mL, 100 mmol, 1 equiv) was 
dissolved in 45 m L anhydrous dichloromethane and cooled to 0 ° C under nitrogen. 
Chlorosulfonyl isocyanate (8.6 mL, 100 mmol, 1 equiv) was dissolved in 15 mL anhydrous 
dichloromethane and was added dropwise to the cyclohexene solution with stirring over 30 minutes. The 
reaction was allowed to warm to room temperature and stirred for 96 h. The resulting solution was cooled 
to 0 °C and quenched with dropwise addition of water until bubbling ceased. Anhydrous sodium sulfite 
(31.6 g, 250 mmol, 2.5 equiv) and sodium biphosphate heptahydrate (70.3 g, 250 mmol, 2.5 equiv) were 
 
 
Figure 3.28. Fmoc-cis-ACHC Monomer Synthesis 
55 
 
dissolved in 500 m L water. This solution and 100 mL chloroform was combined with the reaction 
solution and stirred for 36 h. The organic layer was collected and the aqueous layer was extracted with 
ethyl acetate. The organic layers were combined, dried with magnesium sulfate, and concentrated. The 
resulting yellow solid was re-dissolved in ethyl acetate and recrystallized using pentane to yield white 
crystals (4.81 g, 38.4 mmol, 38% yield). NMR spectra matched previously published results.39 
((1R,6S)-8-oxo-7-azabicyclo[4.2.0]octan-7-yl)methyl butyrate (40): General procedure H 
was employed using 518 mg acetal 39 (3.34 mmol), 34 mL acetone, 0.85 mL vinyl butyrate 
(6.7 mmol), and 1.68 g Lipase PS.  The reaction was stirred for 16 h when NMR spectroscopy 
indicated 40% conversion.  Column chromatography (100% dichloromethane → 50% ethyl 
acetate in dichloromethane → 75% ethyl acetate in hexanes) afforded the esterified product as a yellow 
oil (242 mg, 1.08 mmol, 32% yield). NMR spectra matched previously published results.39 [α]D −18 (c = 
1.0, MeOH); [α]D, lit = −15.5 (c = 1, MeOH).39 
(1S,6R)-7-(hydroxymethyl-7-azabicyclo[4.2.0]octan-8-one (41): General procedure H was 
employed using 518 mg acetal 39 (3.34 mmol), 34 mL acetone, 0.85 mL vinyl butyrate (6.7 
mmol), and 1.68 g  Lipase PS.  T he reaction was stirred for 16 h w hen NMR spectroscopy 
indicated 40% conversion.  Column chromatography (75% ethyl acetate in hexanes) afforded 
the unreacted starting material.  G eneral procedure H was employed using 142 mg recovered starting 
material (0.915 mmol), 9.3 mL acetone, 0.23 mL vinyl butyrate (1.8 mmol), and 463 mg Lipase PS.  The 
reaction was stirred for 36 h w hen NMR spectroscopy indicated 60% conversion.  Column 
chromatography (100% hexanes → 50% ethyl acetate in hexanes → 75% ethyl acetate in hexanes) 
afforded the unreacted starting material in high enantiopurity as a colorless oil (83 mg, 0.54 mmol, 16% 
yield). NMR spectra matched previously published results.39 [α]D = −33 (c = 1.0, MeOH); [α]D, lit = −31.7 
(c = 1, MeOH).39 
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General Procedure I: Acetal Hydrolysis:39 To a solution of N,O-acetal (1 equiv) in methanol was added 
concentrated aqueous ammonium hydroxide.  The reaction mixture was stirred until TLC indicated full 
conversion to product.  The solution was concentrated and dried under vacuum to yield the product. 
(1R,6S)-7-azabicyclo[4.2.0]octan-8-one (42a): General procedure I was employed using 242 
mg compound 40 (1.08 mmol), 15.8 mL methanol, and 1.6 m L concentrated aqueous 
ammonium hydroxide.  The reaction was stirred for 22 h, concentrated, then resubjected using 
15 mL methanol, 8.7 mL concentrated aqueous ammonium hydroxide.  The reaction was stirred for 3 
days then concentrated to afford the product as white crystals (99 mg, 0.79 m mol, 73% yield). NMR 
spectra matched previously published results.39 
(1S,6R)-7-azabicyclo[4.2.0]octan-8-one (42b): General procedure I was employed using 83 
mg compound 41 (0.54 mmol), 8.3 mL methanol, and 0.8 m L concentrated aqueous 
ammonium hydroxide.  The reaction was stirred 3 days then concentrated to afford the product 
as white crystals (62 mg, 0.50 mmol, 93% yield). NMR spectra matched previously published results.39 
(1R,2S)-2-Fmoc-amino-cyclohexanecarboxylic acid (44a): General procedure E 
employed using 123 mg amino acid 43a (0.684 mmol), 0.8 mL water, 137 mg 
potassium bicarbonate (1.36 mmol), and 230 mg Fmoc-OSu (0.682 mmol).  Column 
chromatography (20% ethyl acetate in hexanes → 50% ethyl acetate in hexanes) afforded the product as a 
white foam (115 mg, 0.315 mmol, 46.1% yield). [α]D = −12 (c = 0.50, CHCl3). NMR spectra matched 
previously published results.43 HRMS m/z calcd for [C22H23NO4Na] 388.1525; found 388.1508. 
 (1S,2R)-2-Fmoc-amino-cyclohexanecarboxylic acid (44b): General procedure E 
employed using 76 mg amino acid 43b (0.42 mmol), 0.51 mL water, 84 mg 
potassium bicarbonate (0.84 mmol), and 142 mg Fmoc-OSu (0.421 mmol).  Column 
chromatography (20% ethyl acetate in hexanes → 50% ethyl acetate in hexanes) afforded the product as a 
white foam (97 mg, 0.27 mmol, 50% yield). [α]D = +13 (c = 0.50, CHCl3). NMR spectra matched 
previously published results.43 HRMS m/z calcd for [C22H23NO4Na] 388.1525; found 388.1521. 
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3.2.7. Peptide Synthesis 
 
Peptides were synthesized using standard microwave-assisted Fmoc solid-phase synthesis techniques on 
NovaPEG Rink Amide resin unless otherwise noted.  Peptide cleavage from resin was performed using 
95% trifluoroacetic acid, 2.5% triisopropyl silane, and 2.5% water.  Peptides 9a, 9b, 10a, and 10b were 
synthesized using thiocarbamate-protected monomers.  These monomers were coupled using standard 
microwave-assisted coupling procedures.  For deprotection, the resin was first suspended in 1 mL 
dioxane.  1 mL of 0.04 M solution of Oxone in water was added to the suspension and stirred for 90 
minutes.  After this time, the solution was drained and the resin washed five times with 1:1 dioxane/water 
and washed three times with DMF.  Peptides were purified by HPLC on a C18 preparative column using 
gradients between 0.1% TFA in water and 0.1% TFA in acetonitrile.  All peptides were >95% pure by 
analytical HPLC on a C18 column. Identities of peptides were confirmed using a Voyager DE Pro 
MALDI-TOF instrument (Appendix A).   The samples of peptides 10a and 10b used for NMR analysis 
were synthesized using an O-ethyl thiocarbamate protected β-amino acid rather than the O-butyl 
thiocarbamate protected amino acids used in subsequent syntheses.  A sample of peptide 9a synthesized 
using the O-butyl thiocarbamate protected monomer and showed an identical 1H NMR spectrum 
(Appendix A), confirming that the length of the alkyl chain on the protecting group has no effect on the 
synthesis. 
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3.2.8. NMR Sample Preparation and Data Collection 
 
NMR samples were prepared by dissolving 2-3 mg peptide in 750-850 µL de-gassed buffer solution (0.1 
M NaOAc-d3, 90% H2O/D2O, uncorrected pH 3.8) to make ~2 mM solutions.  Use of an acidic pH 
discourages aggregation with this system.29  3-(Trimethylsilyl)-1-propanesulfonic acid sodium salt (DSS, 
50 mM in water) was added to a final concentration of ~0.2 mM DSS in the sample for use as a reference.  
Each solution was passed through a 0.2 µm syringe filter, transferred to an NMR tube, and stored until 
analysis.  The NMR tube headspace was purged with a stream of nitrogen prior to capping. 
NMR spectra of peptides were recorded on a Bruker-Avance-600 or Bruker Avance-700 
spectrometer (Appendix A). Chemical shifts are reported relative to DSS (0 ppm).  NMR spectra were 
measured at 277 K. TOCSY, NOESY, and COSY pulse programs used excitation-sculpted gradient-pulse 
solvent suppression.  All experiments were obtained using 2048 data points in the direction dimension 
and 512 data points in the indirect dimension. TOCSY were acquired with a mixing time of 60 or 80 ms 
and NOESY were acquired with a mixing time of 200 ms. 
 
 
3.2.9. NMR Data Analysis and Structure Determination 
 
The Sparky software package (T. D. Goddard and D. G. Kneller, SPARKY 3, University of California, 
San Francisco) was used to analyze 2D NMR data.  Backbone chemical shift assignments were generated 
and each peptide was analyzed for qualitative NOE’s indicative of folding.  Peptides that showed a high 
degree of folding were fully assigned and inter-residue NOE’s were tabulated.  NOE integration values 
were converted to distance restraints using the formula I = cr-6 where I is intensity, c is a co nstant 
(determined using resolved diastereotopic CH2 groups from Tyr4, Gly7, and/or Phe9), and r is distance.53  
The distances were then sorted and classified as strong (≤2.7 Å), medium (≤3.5 Å), weak (≤4.5 Å), or 
very weak (≤5.5 Å) to generate distance restraints (Appendix A). 
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The Crystallography and NMR system (CNS) software package was used to generate 3D 
structures.54,55   Patches were written to accommodate β-residues.  CNS contains angle, charge repulsion, 
and bond length restraints for α-residues; these restraints were adapted for use with unnatural β-residues.  
The calculated distance restraints from NOESY measurements were used in 100 simulated annealing runs 
using default suggested parameters for protein NMR. Structures including any NOE distance-restraint 
violations (>0.5 Å) were discarded and the 20 lowest energy structures were obtained. The minimum 
energy average of these 20 structures was inspected to identify H-bonding contacts. These contacts were 
then included in an additional restraint file and the annealing process repeated to generate an ensemble of 
20 low energy structures and a minimized average structure for each peptide.  
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3.3. CONCLUSIONS 
 
Several conclusions can be drawn from this study, all of which help further the goal of establishing 
methodology for introducing β-residues into β-sheets and eventually tertiary structures.  First, one 
enantiomer of the β3-monomers and both enantiomers of the syn-β2,3-monomers allow somewhat native-
like folding when inserted into the model β-sheet system.  The peptide containing the β3-monomer 
provided a distorted hairpin structure while the two peptides containing syn-β2,3-monomers demonstrate a 
staggered conformation when inserted into the β-sheet.  Of the two syn-β2,3-monomers that template 
folding, the L-stereochemistry presents a more natural display of side-chains in the β-hairpin. 
 Another important conclusion is that of all of the β-residues that allow the peptide to fold as a β-
hairpin, none of the monomers studied provide enough steric influence to prevent inversion of the H-bond 
pattern found in the prototype β-sheet model system.   
Based on the data shown from this study, the next step in this project will be to use functionalized 
L-configured syn-β2,3-monomers in a larger sheet-forming protein.  Use of the monomers with an L-
configuration mimics the natural configuration of α-residues.  Using functionalized side-chains will 
provide a mimic that can participate in side-chain−side-chain interactions; that are vital for protein 
folding.   In addition to use of an L-configured monomer, substitution pattern must also be considered in 
peptide design.  While a 1:1 α- → β-residue substitution causes side-chain inversion, it is our hypothesis 
that other substitution patterns could prevent this. 
In future studies, both functionalized β2,3-monomers and effect of substitution pattern will be 
investigated to further the goal of designing a universal methodology for β-residue use in larger protein 
tertiary structures. 
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4.0. INSERTION OF FUNCTIONALIZED SYN-β2,3-RESIDUES INTO β-HAIRPINS 
 
4.1. GOALS 
 
In order to establish a methology useful for inclusion of β-residues in a protein that has tertiary folded 
structure, protein GB1 has been chosen as a model system.  Recall that GB1 contains an α-helix as well as 
four strands forming two β-sheets (Figure 4.1).   
 
 
 
 
 
 
 
Hybrid α/β peptides that form mimics of α-helices have been well-studied and our previous work 
established some parameters for design rules to mimic β-sheet secondary structures.  Although several 
monomer types were highlighted as effective at promoting sheet formation, important questions remain 
unanswered: 1) Will a side-chain functionalized β2,3-residue with an L-configuration promote favorable 
side-chain−side-chain interactions important for folding in a larger β-sheet? 2) Can an appropriate α- to β-
 
MTYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTYDDATKTFTVTE 
 
 
Figure 4.1. Structure of Protein GB1 
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residue substitution pattern eliminate the problem of side-chain inversion noted in our previous study? 3) 
What are the quantitative thermodynamic consequences of modifying the backbone of a β-sheet? 
 
 
 
 
4.2. β-SHEET MODEL SYSTEM AND β-RESIDUES REQUIRED 
 
The four strands of GB1 form a β-sheet (Figure 4.2).  The long-term goal of the project is to introduce β-
residues into full-length GB1 mimics.     
 
  
 
 
Figure 4.2. β-Sheet Structure of GB1 
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Both the N-terminal and the C-terminal hairpin fragments of GB1 have been studied to measure their 
folding apart from the remainder of the protein.  The N-terminal fragment shows no folding in water and 
only moderate folding in 30% trifluoroethanol.56  The C-terminal fragment, 1, has been shown to have a 
roughly 40% folded population at 278 K.28   
1 H-GEWTYDDATKTFTVTE-OH 
 Using this fragment as a model system helps narrow down the residues essential for this study.  
Residues T4, Y5, F12, and T13 can be found in the middle of the sheets in peptide 1 (Figure 4.3) and should 
not therefore interfere with the turn region.  Because these residues are also found in the center of the 
sheets, any folded structure destabilization caused by substitution of these residues should be obvious via 
NOE analysis. 
 
 
 
 
 
 
 With this model system and specific residues in mind, it is important to consider the effect of 
substitution pattern.  Our prior work has shown that substituting a single β-residue in place of an α-
residue results in side-chain inversion.  We hypothesize that replacing two α-residues with either one or 
two β-residues should prevent side-chain inversion.  Use of one β-residue in place of two α-residues will 
effectively result in an amide deletion (Figure 4.4A) while use of two β-residues in place of two α-
residues will result in the lengthening of the backbone by two carbon atoms (Figure 4.4B).  In the case of 
 
 
Figure 4.3. Hairpin Structure of Compound 1 
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a 2:2 α/β substitution, the extra backbone carbons could be simple methylene units or substituted with 
methyl groups to make a sheet-promoting syn-β2,3-monomer. 
 
 
 
 
 
 
 
 To simplify the monomer synthesis required for this study, the hydrophilic side-chains of residues 
T4 and T13 will be replaced with methyl groups.  These residues are oriented in the solvent-exposed face 
of the GB1 β-sheet; the impact of the functional group mutation should be negligible in regards to folded 
structure.   
 To determine which substitution pattern is more energetically favorable, four designs will be 
examined by quantitatively comparing the folding thermodynamics of each.  The first two designs utilize 
syn-β2,3-residues and a combination of β2- and β3-residues (Figure 4.5A).  Design 1 incorporates L-
configured syn-β2,3-residues in a 2:1 α/β substitution pattern (Figure 4.5B).  Design 2 uses the same 
substitution pattern, but the hydrophilic methyl side-chains are completely removed.  Specific β2- and β3-
residues have been chosen to reflect the appropriate side-chain display found in the natural system.  
A. 2:1 α/β Substitution 
 
B. 2:2 α/β Substitution 
 
 
Figure 4.4. β-Residue Substitution Patterns 
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Comparison of folded structure using syn-β2,3- and β2/β3-residues will provide insight into the additional 
stability provided by the steric hindrance to rotation found in syn-β2,3-residues. 
 The next two designs use the same residue types with a different substitution pattern.  Design 3 
uses syn-β2,3-residues in a 2:2 α/β substitution pattern (Figure 4.5C).  The β2,3-residues chosen for this 
pattern incorporate both side-chains from the original α-residues as well as additional methyl groups to 
restrict rotation around the Cα-Cβ bond.   Design 4 incorporates the side-chains from the original α-
residues but does not include the extra methyl groups found in Design 3.  Again, comparison of folded 
structure with and without the additional methyl groups will provide insight into the additional stability 
found in syn-β2,3-residues. 
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Figure 4.5. Residue Types and Substitution Patterns Chosen for Study 
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 In order to test the four backbone modification strategies shown above, several protected 
monomers will be required (Figure 4.6).  β2,3-amino acids 3-5 can be synthesized using the same 
thiazinone strategy used previously.  β3-amino acids 6 and 7 are commercially available.  β2-amino acids 
8 and 9 can be synthesized using the same diastereoselective Mannich strategy utilized previously.  These 
syntheses attempts are currently underway; we have four of the seven monomers in hand. 
 
 
 
 
 
 
 
  
 
 
Figure 4.6. Protected β-Monomers Necessary for Study 
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4.3. THERMODYNAMIC ANALYSIS 
 
Using the chosen model β-hairpin system, the thermodynamic consequences of residue substitution can 
be measured.  As previously discussed, given a known folded population, K can be calculated (Figure 
4.7).46 
 
 
 
𝐾 = 𝑣1 − 𝑣 
 
 
Figure 4.7. Equilibrium Constant of Folding 
 
 
 
Using this K value, ΔG° can be calculated (Figure 4.8): 
 
 
 
∆𝐺° = −𝑅𝑇𝑙𝑛(𝐾) 
 
 
Figure 4.8. Gibbs Free Energy of Folding 
 
 
 
Folded population can be determined from the chemical shift data for the peptide of interest, a fully 
unfolded control, and a full folded control (Figure 4.9).57 
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𝛥𝑎𝑖𝑟𝑝𝑖𝑛 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 (%) = 𝛿𝑜𝑏𝑠 − 𝛿𝑢𝑛𝑓𝑜𝑙𝑑𝑒𝑑
𝛿𝑓𝑜𝑙𝑑𝑒𝑑 − 𝛿𝑢𝑛𝑓𝑜𝑙𝑑𝑒𝑑
 
 
Figure 4.9. Hairpin Population 
 
 
 
 By incorporating the unnatural residues into the model peptide and using the substitution patterns 
discussed earlier, NMR analysis can give the chemical shift data necessary to calculate folded population 
assuming folded and unfolded controls are available.  Folded controls can be obtained by adding cysteine 
residues to the termini of the peptide of interest and generating a disulfide linkage (Figure 4.10a).58  To 
generate unfolded controls, the peptide sequence of interest can be split at the turn region to generate two 
short fragments (Figure 4.10b). 
 
   
 
 
Figure 4.10. Folded and Unfolded Controls Required for Study 
 
A 
B 
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With a means to find the chemical shift deviation and therefore folded population, ΔG° can be calculated.  
ΔΔG° values between the mutant peptides and model peptide can be calculated to give an energetic value 
for the folded stability imparted or lost by the mutations. 
 In addition to ΔΔG° values, ΔH, ΔS, and ΔCp of peptide folding can also be calculated (Figure 
4.11).46 
 
 
 
 
 
 
 
In this equation, ΔδHlimit is the maximum chemical shift deviation between the fully folded and unfold 
controls while ΔδHα is the chemical shift deviation between the peptide of interest and unfolded controls.  
NMR analysis can give chemical shift deviation values over a range of temperatures and curve-fitting 
software can be used to calculate values of ΔH, ΔS, and ΔCp.  These thermodynamic values will give 
another quantifiable measure of the impact of the β-residue substitutions on folding.   
 
  
∆𝛿𝐻𝛼 = ∆𝛿𝐻𝑙𝑙𝑙𝑙𝑙𝑒� 𝑥𝑅𝑅�
�1 + 𝑒� 𝑥𝑅𝑅��  
𝑥 = 𝑇 �𝛥𝛥°298 + ∆𝐶°𝑝 ln � 𝑇298�� − �𝛥𝛥°298 + ∆𝐶°𝑝(𝑇 − 298)� 
 
 
Figure 4.11. Thermodynamics of Folding 
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4.4. REFINEMENT OF β-HAIRPIN MODEL SYSTEM 
Despite our hopes, peptide 1 proved unsuitable for the thermodynamic study for two reasons.  First, due 
to the number of threonine residues found in this system, there is significant overlap of resonances in the 
2D NMR.  Second, because this system is only 40% folded at 278 K, it is difficult to establish a melting 
curve throughout a wide range of temperatures.  It is for these reasons that a slightly modified version of 
this peptide was analyzed.  The Andersen lab has shown that hairpin peptide 10 is roughly 86% folded at 
298 K.59   
10 H-KKWTYNPATGKFTVQE-OH 
This peptide contains the same hydrophobic core residues contained in 1 and has a reported melting 
temperature of about 60 °C.  Due to the higher melting temperature, it was hoped that the temperature 
range of an unfolding transition could be measured within the limits of aqueous solvent (between 278 K 
and 368 K).  Unfortunately, we found 10 to be too stable for our purposes; very little unfolding was 
observed at temperatures up to 328 K, and a melting curve could not be constructed.  Temperatures above 
328 K showed fast solvent exchange of the amide protons necessary for assigning chemical shifts.  The 
cross-peaks in the TOCSY associated with these protons are lost at higher temperatures. 
 As an alternative to peptide 10, we are currently investigating the use of peptides 11 and 12 as 
models for the thermodynamic analysis of the α→β substitution strategies.  
    11 H-GEWTYNPATGKFTVTE-OH 
12 H-GEWAYNPATGKFAVTE-NH2 
Peptide 11 has been reported to be  roughly 74% folded at 298 K with a Tm of about 47 °C.
59  Peptide 12 
is designed to be slightly less stable by replacing sheet-promoting residues T4 and T13 with alanine 
residues.  It is our hope that one of these two peptides will provide a prototype β-hairpin useful for 
thermodynamic study.  Data analysis of these peptides is currently ongoing.   
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4.5. CONCLUSIONS 
 
 Overall, five sets of peptides will be studied using six different β-residues.  Each set of peptides 
will include the peptide to be analyzed, a cyclized folded control, and two strands to serve as unfolded 
controls.  The current basis sequence for these sets will be either model peptide 11 or alanine-substituted 
peptide 12.  If these peptides show melting ranges appropriate for NMR analysis, mutants will be 
synthesized using the four design strategies mentioned previously, incorporating either L-configured β2,3-
residues or a combination of β2- and β3-residues.   These mutants will reflect both possible substitution 
patterns hypothesized to prevent side-chain inversion: 2:2 α/β and 2:1 α/β substitution.  These peptides 
will be analyzed by NMR at varying temperatures in order to calculate thermodynamic data that will 
reveal the impact of the β-residue substitutions on β-sheet folded structure.  This understanding of this 
impact can then be used in designing substitution methodologies which can be used in the full-length 
GB1 β-sheet. 
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APPENDIX A. PROBING β-RESIDUE IMPACT ON β-SHEET FORMATION SI 
 
 
 
 
Figure A.1. 1H-NMR of Compound 24a 
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Figure A.2. 1H-NMR of Compound 25a 
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Figure A.3. 13C-NMR of Compound 25a 
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Figure A.4. 1H-NMR of Compound 26a 
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Figure A.5. 13C-NMR of Compound 26a 
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Figure A.6. 1H-NMR of Compound 24b 
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Figure A.7. 1H-NMR of Compound 25b 
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Figure A.8. 13C-NMR of Compound 25b 
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Figure A.9. 1H-NMR of Compound 26b 
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Figure A.10. 13C-NMR of Compound 26b 
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Figure A.11. 1H-NMR of Compound 27 
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Figure A.12. 13C-NMR of Compound 27 
85 
 
 
 
Figure A.13. 1H-NMR of Compound 28 
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Figure A.14. 13C-NMR of Compound 28 
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Figure A.15. 1H-NMR of Compound 29a 
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Figure A.16. 1H-NMR of Compound 30a 
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Figure A.17. 13C-NMR of Compound 30a 
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Figure A.18. 1H-NMR of Compound 29b 
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Figure A.19. 1H-NMR of Compound 30b 
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Figure A.20. 13C-NMR of Compound 30b 
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Figure A.21. 1H-NMR of Peptide 10a Derived from O-Ethyl Thiocarbamate 
10a, derived from
 O
-
ethyl thiocarbam
ate 
protected m
onom
er 
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Figure A.22. 1H-NMR of Peptide 10a Derived from O-Butyl Thiocarbamate 
10a, derived from
 O
-
butyl thiocarbam
ate 
protected m
onom
er 
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Table A1. MALDI-TOF data for peptides 2a-18a and 2b-18b 
 
# [M+H]
+ m/z 
Calculated Observed 
2a 1507.8 1508.3 
3a 1504.9 1505.1 
4a 1504.9 1505.0 
5a 1504.9 1504.7 
6a 1504.9 1504.4 
7a 1532.9 1532.9 
8a 1532.9 1532.9 
9a 1532.9 1533.0 
10a 1532.9 1533.0 
11a 1500.8 1501.0 
12a 1500.8 1501.0 
13a 1500.8 1500.6 
14a 1500.8 1500.6 
15a 1528.9 1528.8 
16a 1528.9 1528.8 
17a 1528.9 1528.6 
18a 1528.9 1528.5 
2b 1507.8 1507.7 
3b 1504.9 1504.6 
4b 1504.9 1505.0 
5b 1504.9 1504.7 
6b 1504.9 1504.4 
7b 1532.9 1532.9 
8b 1532.9 1532.7 
9b 1532.9 1533.0 
10b 1532.9 1533.0 
11b 1500.8 1500.5 
12b 1500.8 1500.6 
13b 1500.8 1500.6 
14b 1500.8 1500.4 
15b 1528.9 1528.5 
16b 1528.9 1528.9 
17b 1528.9 1528.5 
18b 1528.9 1528.6 
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Table A.2. Backbone 1H Chemical Shift Assignments for Peptides 2a-18a and 2b-18b. 
 R1 W2 X3 Y4 V5 P6 G7 K8 F9 X10 V11 Q12 
# Hα H Hα H Hα Hα' Hβ Hβ' H Hα H Hα Hα H Hα Hα ' H Hα H Hα H Hα Hα' Hβ Hβ' H Hα H Hα 
2a 4.04 8.88 4.88 8.75 4.44 − − − 8.63 4.87 8.70 4.52 4.37 8.39 3.75 3.99 7.90 4.59 8.90 4.63 8.55 4.49 − − − 8.32 3.86 8.42 4.25 
2b 4.05 8.94 4.62 8.04 4.15 − − − 8.22 4.20 8.01 4.21 4.22 8.50 3.89 3.92 8.20 4.27 8.48 4.74 8.20 4.34 − − − 8.42 4.07 8.63 4.24 
3a 3.95 8.78 4.66 7.96 1.65 2.02 3.89 − 8.05 4.85 8.77 4.07 4.36 8.31 3.81 3.88 7.97 4.37 8.39 4.27 8.02 1.98 2.43 3.99 − 8.39 4.16 8.67 3.99 
3b 3.91 8.72 4.66 8.15 1.83 2.11 3.88 − 8.14 4.59 8.21 3.74 4.21 8.45 3.82 3.85 8.06 4.19 8.21 4.56 8.13 2.31 2.54 4.03 − 8.28 4.15 8.60 3.88 
4a 4.01 8.89 4.71 7.86 2.17 2.22 3.74 − 8.31 4.70 8.63 4.45 4.40 8.47 3.87 3.94 8.04 4.39 8.41 4.36 8.02 2.31 2.45 3.98 − 8.32 4.04 8.61 4.26 
 
4b 4.01 8.90 4.70 7.95 2.22 2.30 3.78 − 8.34 4.52 8.13 4.26 4.23 8.53 3.90 3.94 8.17 4.25 8.28 4.62 8.14 2.39 2.52 4.06 − 8.30 4.06 8.63 4.29 
5a 3.98 8.83 4.58 7.73 1.87 − 3.00 3.32 7.84 4.69 8.58 4.37 4.38 8.40 3.82 3.92 8.01 4.31 8.36 4.44 8.03 2.29 − 3.16 3.41 8.23 4.00 8.64 4.27 
5b 3.98 8.89 4.63 8.11 1.93 − 3.07 3.48 7.99 4.44 8.02 4.18 4.16 8.46 3.87 3.90 8.12 4.22 8.30 4.60 8.16 2.32 − 3.31 3.44 8.34 4.01 8.66 4.28 
6a 3.88 8.61 4.74 8.34 2.15 − 3.10 3.57 8.21 4.75 8.68 3.78 4.30 8.12 3.84 3.87 7.97 4.24 8.11 4.28 7.92 2.34 − 3.23 3.36 8.35 4.12 8.59 4.03 
6b 3.89 8.60 4.74 8.33 2.18 − 3.16 3.54 8.28 4.67 8.29 3.72 4.19 8.44 3.82 3.86 8.11 4.22 8.16 4.49 8.06 2.38 − 3.33 3.37 8.35 4.13 8.55 4.04 
7a 3.82 8.58 4.86 8.32 2.53 − 3.84 − 8.18 4.76 8.73 3.38 4.31 7.94 3.80 3.84 7.86 4.20 8.15 4.47 8.03 2.75 − 3.80 − 8.26 4.24 8.58 3.76 
7b 3.82 8.59 4.84 8.32 2.53 − 3.82 − 8.19 4.69 8.32 3.38 4.18 8.42 3.78 3.82 7.96 4.15 8.19 4.62 8.15 2.75 − 3.87 − 8.27 4.23 8.60 3.68 
8a 4.00 8.91 4.81 7.58 2.61 − 3.33 − 8.39 4.66 8.58 4.47 4.45 8.40 3.88 3.91 7.98 4.27 8.29 4.52 7.83 2.78 − 3.70 − 8.34 4.04 8.57 4.24 
8b 3.98 8.89 4.80 7.69 2.62 − 3.47 − 8.32 4.56 8.18 4.32 4.29 8.55 3.91 3.94 8.13 4.26 8.30 4.66 7.94 2.75 − 3.80 − 8.33 4.00 8.60 4.29 
9a 4.08 8.98 4.80 7.74 2.21 − 3.77 − 8.16 5.08 8.96 4.57 4.37 8.57 3.69 4.05 7.97 4.58 8.70 4.45 8.11 2.62 − 3.83 − 8.80 4.14 8.82 4.20 
9b 4.00 8.96 4.75 7.88 2.18 − 3.61 − 8.43 4.64 8.24 4.31 4.30 8.56 3.90 3.93 8.14 4.23 8.50 4.66 7.95 2.55 − 3.82 − 8.52 3.98 8.69 4.28 
10a 4.08 9.01 4.90 7.82 2.50 − 3.72 − 8.46 5.07 8.93 4.54 4.39 8.69 3.79 4.08 8.03 4.66 8.77 4.22 7.84 2.48 − 3.69 − 8.06 4.04 8.71 4.22 
10b 4.05 8.98 4.86 7.79 2.39 − 3.64 − 8.57 4.51 8.09 4.23 4.20 8.50 3.88 3.93 8.17 4.25 8.53 4.70 7.96 2.59 − 3.82 − 8.53 4.06 8.67 4.28 
11a 4.00 8.79 4.53 8.10 1.76 − 3.97 − 7.84 4.77 8.77 4.29 4.40 8.47 3.85 8.94 8.09 4.44 8.50 4.06 8.01 2.32 − 4.18 − 8.12 4.17 8.64 4.19 
11b 4.00 8.75 4.55 8.22 1.85 − 4.07 − 8.04 4.59 8.28 3.99 4.23 8.48 3.87 3.92 8.21 4.22 8.25 4.51 8.04 2.50 − 4.19 − 8.29 4.17 8.62 4.16 
12a 4.04 8.99 4.60 7.89 2.46 − 3.92 − 8.27 4.79 8.63 4.48 4.41 8.58 3.90 3.97 8.08 4.52 8.53 4.10 7.90 2.51 − 3.98 − 8.13 4.00 8.59 4.26 
12b 4.02 8.94 4.55 7.87 2.43 − 3.90 − 8.30 4.55 8.17 4.24 4.23 8.52 3.90 3.94 8.18 4.29 8.35 4.50 8.14 2.58 − 4.14 − 8.33 4.05 8.67 4.28 
13a 3.88 8.61 4.68 8.11 2.86 − 4.34 − 7.90 4.55 8.44 4.06 4.40 8.22 3.73 3.85 8.01 4.21 8.17 4.50 7.68 3.05 − 4.32 − 8.15 3.86 8.55 4.25 
13b 3.91 8.70 4.70 8.14 2.87 − 4.35 − 8.12 4.30 7.88 4.11 4.18 8.44 3.84 3.87 8.06 4.19 8.24 4.60 7.76 3.06 − 4.39 − 8.16 3.88 8.59 4.25 
14a 4.02 8.85 4.59 7.62 2.73 − 4.04 − 8.16 4.49 8.54 4.15 4.40 8.25 3.87 3.90 8.09 4.32 8.40 4.36 7.63 2.99 − 4.22 − 8.16 4.18 8.52 4.19 
14b 4.10 8.85 4.66 7.70 2.78 − 4.11 − 8.25 4.43 8.13 4.14 4.27 8.45 3.90 3.95 8.21 4.24 8.39 4.47 7.60 3.02 − 4.23 − 8.12 4.17 8.53 4.18 
15a 3.82 8.47 4.72 8.66 2.34 − 3.87 − 8.22 4.74 8.70 3.32 4.28 7.91. 3.79 3.85 7.95 4.18 7.85 4.40 8.26 2.47 − 3.89 − 8.24 4.27 8.58 3.60 
15b 3.82 8.44 4.71 8.64 2.35 − 3.86 − 8.21 4.68 8.29 3.30 4.14 8.38 3.80 3.84 8.03 4.15 7.99 4.53 8.34 2.46 − 3.88 − 8.28 4.24 8.60 3.62 
16a 3.94 8.70 4.54 7.65 2.10 − 3.70 − 8.15 4.68 8.41 4.39 4.40 8.34 3.85 3.90 8.14 4.29 8.13 4.50 8.20 2.28 − 3.81 − 8.20 3.99 8.59 4.28 
16b 3.97 8.78 4.60 7.75 2.11 − 3.68 − 8.17 4.54 8.13 4.25 4.24 8.52 3.91 3.95 8.22 4.28 8.17 4.50 8.20 2.26 − 3.82 − 8.22 3.99 8.59 4.29 
17a 3.86 8.62 4.83 8.09 2.50 − 4.23 − 7.60 4.62 8.52 3.91 4.39 8.16 3.65 3.88 7.95 4.24 8.19 4.57 7.78 2.72 − 4.16 − 8.05 3.90 8.51 4.20 
17b 3.95 8.72 4.76 7.97 2.37 − 4.12 − 7.80 4.33 7.96 4.01 4.21 8.46 3.85 3.88 8.09 4.22 8.25 4.67 7.90 2.70 − 4.28 − 8.05 3.94 8.57 4.18 
18a 4.01 8.84 4.69 7.48 2.42 − 3.88 − 7.93 4.49 8.50 4.30 4.42 8.27 3.85 3.90 8.05 4.34 8.41 4.42 7.59 2.72 − 4.12 − 8.01 4.16 8.53 4.23 
18b 4.09 8.85 4.70 7.55 2.47 − 3.99 − 7.95 4.44 8.23 4.23 4.29 8.48 3.93 3.96 8.22 4.29 8.39 4.52 7.65 2.74 − 4.13 − 8.00 4.13 8.54 4.24 
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Table A.3. Proton chemical shifts of α-peptide 2a and α/β-peptides 3a, 9a, and 10a.  
 
Residue Atom 2a 3a 9a 10a 
R1 HA 4.043 3.954 4.082 4.079 
R1 HB 1.9 1.867 1.881 1.925 
R1 HG 1.595 1.541 1.54 1.565 
R1 HG' x x x 1.64 
R1 HD 3.152 3.152 3.122 3.159 
R1 HE 7.218 7.253 7.277 7.385 
R1 HH 6.514 6.535 6.535 6.594 
R1 HH' 6.946 6.998 7.029 7.119 
W2 H 8.882 8.775 8.977 9.011 
W2 HA 4.88 4.658 4.798 4.895 
W2 HB 2.972 3.097 3.162 3.234 
W2 HB' 3.048 x 3.254 x 
W2 HD1 7.154 7.256 7.201 7.229 
W2 HE1 10.21 10.278 10.219 10.296 
W2 HE3 7.292 7.652 7.657 7.715 
W2 HH2 7.216 7.208 7.221 7.183 
W2 HZ2 7.449 7.483 7.45 7.488 
W2 HZ3 7.054 7.124 7.145 7.249 
X3 H 8.749 7.957 7.742 7.815 
X3 HA 4.441 1.654 2.205 2.497 
X3 HA' x 2.021 x x 
X3 HB 1.879 3.888 3.773 3.719 
X3 HB' 1.95 x x x 
X3 HE 6.954 x 0.036 0.907 
X3 HE' 7.425 x x x 
X3 HD x 0.749 0.766 0.259 
X3 HD' x x 0.878 0.359 
X3 HG 2.066 1.462 1.25 1.323 
X3 HG' 2.115 x x x 
Y4 H 8.632 8.049 8.158 8.457 
Y4 HA 4.866 4.851 5.081 5.074 
Y4 HB 2.732 2.64 2.679 2.676 
Y4 HB' 2.901 2.857 2.759 2.773 
Y4 HD 6.824 6.956 6.871 6.947 
Y4 HE 6.705 6.778 6.736 6.772 
V5 H 8.7 8.768 8.959 8.926 
V5 HA 4.515 4.065 4.565 4.542 
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Table A.3. (Continued) 
 
Residue 
Atom 2a 3a 9a 10a 
V5 HB 2.021 1.877 1.945 1.895 
V5 HG 0.911 0.805 0.861 0.828 
V5 HG' x 0.869 0.942 0.908 
P6 HA 4.371 4.359 4.365 4.388 
P6 HG 1.956 1.918 2.113 2.06 
P6 HG' 2.049 x 2.054 2.136 
P6 HB 2.344 2.234 1.971 1.983 
p6 HB' x x 2.377 2.388 
P6 HD 3.775 3.317 3.856 3.851 
P6 HD' x 3.76 x x 
G7 H 8.391 8.312 8.567 8.685 
G7 HA 3.754 3.812 3.694 3.789 
G7 HA' 3.987 3.884 4.046 4.08 
K8 H 7.901 7.968 7.974 8.025 
K8 HA 4.585 4.371 4.58 4.656 
K8 HB 1.741 1.746 1.762 1.784 
K8 HB' 1.816 x 1.825 1.873 
K8 HD 1.664 1.61 1.652 1.687 
K8 HE 2.981 2.925 2.978 3.007 
K8 HG 1.344 1.249 1.324 1.362 
K8 HG' x 1.297 1.399 1.427 
K8 QZ 7.621 7.595 7.623 7.634 
F9 H 8.901 8.392 8.704 8.772 
F9 HA 4.625 4.267 4.446 4.222 
F9 HB 2.794 2.83 2.872 2.797 
F9 HB' 2.896 x 2.954 2.845 
F9 HZ 7.03 x 7.11 6.956 
F9 HD 6.862 7.016 6.826 6.66 
F9 HE 7.067 7.251 7.172 7.155 
X10 H 8.547 8.022 8.108 7.838 
X10 HA 4.494 1.98 2.622 2.48 
X10 HA' x 2.443 x x 
T10 HB 4.023 3.989 3.832 3.686 
X10 HG 1.125 1.652 1.66 1.261 
X10 HG' x 0.813 x x 
X10 HD x x 0.764 0.151 
X10 HD' x x 1.005 0.293 
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Table A.3. (Continued) 
 
Residue Atom 2a 3a 9a 10a 
X10 HE x x 0.271 0.975 
V11 H 8.318 8.388 8.804 8.062 
V11 HA 3.86 4.157 4.136 4.035 
V11 HB 1.748 2.064 2.21 2.007 
V11 HG 0.76 0.95 0.996 0.849 
V11 HG' x x 1.061 0.926 
Q12 H 8.424 8.667 8.822 8.713 
Q12 HA 4.251 3.99 4.198 4.215 
Q12 HB 1.828 1.734 1.985 1.967 
Q12 HB' 2.029 1.942 2.123 2.101 
Q12 HE' 6.931 7.014 6.983 7.264 
Q12 HE' 7.517 7.228 7.679 7.747 
Q12 HZ 7.249 7.232 7.28 6.664 
Q12 HZ' 7.752 7.59 7.746 7.121 
Q12 HG 2.267 2.184 2.376 2.349 
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Table A.4. Peptide 2a NOE distance restraints. 
 
Residue Proton Residue Proton Distance 
5 V HA 6 P QD 2.7 
6 P QD 5 V HA 2.7 
4 Y HA 5 V H 2.7 
9 F HA 10 T H 2.7 
2 W HA 3 Q H 2.7 
8 K HA 9 F H 2.7 
10 T HA 11 V H 2.7 
11 V H 10 T HA 2.7 
1 R HA 2 W H 2.7 
11 V HA 12 Q H 2.7 
4 Y H 3 Q HA 2.7 
7 G HA1 7 G H 2.7 
9 F H 8 K HA 2.7 
3 Q HA 4 Y H 2.7 
12 Q H 11 V HA 2.7 
2 W H 1 R HA 2.7 
10 T H 9 F HA 2.7 
7 G H 6 P HA 2.7 
6 P HA 7 G H 2.7 
12 Q HB1 12 Q H 3.5 
7 G H 8 K H 3.5 
4 Y HA 9 F HA 3.5 
2 W HA 11 V HA 3.5 
8 K H 7 G H 3.5 
1 R QB 2 W H 3.5 
1 R HA 2 W HD1 3.5 
7 G HA1 8 K H 3.5 
7 G HA2 8 K H 3.5 
5 V H 8 K H 3.5 
11 V H 10 T HB 3.5 
8 K H 5 V H 3.5 
4 Y H 3 Q HB2 3.5 
2 W HB1 3 Q H 3.5 
4 Y HB2 5 V H 3.5 
3 Q H 2 W HB2 3.5 
9 F H 8 K HB2 3.5 
8 K HB2 9 F H 3.5 
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Table A.4. (Continued) 
 
Residue Proton Residue Proton Distance 
8 K H 7 G HA1 3.5 
4 Y HA 10 T H 3.5 
4 Y H 3 Q HB1 3.5 
4 Y H 3 Q HG1 3.5 
10 T H 3 Q H 3.5 
9 F HB2 10 T H 3.5 
2 W HB2 3 Q H 3.5 
5 V H 4 Y HB1 3.5 
9 F HA 5 V H 3.5 
3 Q H 10 T H 3.5 
4 Y HB1 5 V H 3.5 
11 V HB 12 Q H 3.5 
8 K H 7 G HA2 3.5 
10 T H 9 F HB2 3.5 
8 K HB1 9 F H 3.5 
5 V QQXG 6 P QD 4.5 
12 Q H 3 Q H 4.5 
4 Y QE 9 F HB1 4.5 
8 K HA 4 Y QD 4.5 
8 K HA 4 Y QE 4.5 
2 W H 1 R QG 4.5 
8 K QG 9 F H 4.5 
2 W HE3 3 Q HA 4.5 
10 T QXGT 11 V H 4.5 
12 Q H 11 V QQXG 4.5 
7 G HA1 4 Y QD 4.5 
5 V H 4 Y QD 4.5 
4 Y HA 9 F QD 4.5 
9 F QD 10 T H 4.5 
5 V H 6 P QD 4.5 
10 T H 9 F QD 4.5 
9 F H 10 T H 4.5 
9 F HB1 10 T H 4.5 
4 Y QD 5 V H 4.5 
2 W HE3 9 F QD 4.5 
10 T H 11 V H 4.5 
9 F H 8 K H 4.5 
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Table A.4. (Continued) 
 
Residue Proton Residue Proton Distance 
2 W HA 12 Q H 4.5 
10 T H 9 F HB1 4.5 
11 V H 10 T H 4.5 
4 Y HB2 2 W HE3 4.5 
4 Y HB1 9 F QE 4.5 
4 Y HA 3 Q HA 4.5 
9 F H 4 Y QE 4.5 
10 T HA 2 W HE3 4.5 
8 K H 6 P HA 4.5 
9 F HA 4 Y QD 4.5 
3 Q H 2 W HE3 4.5 
8 K H 9 F H 4.5 
9 F H 4 Y QD 4.5 
12 Q HA 11 V HA 4.5 
10 T H 9 F H 4.5 
5 V HA 7 G H 4.5 
6 P HA 8 K H 4.5 
7 G H 5 V H 4.5 
2 W HE3 10 T H 4.5 
2 W HE3 10 T HA 4.5 
6 P QB 7 G H 4.5 
2 W HE3 3 Q H 4.5 
11 V HA 3 Q H 4.5 
7 G HA1 9 F HB2 4.5 
4 Y QD 8 K H 4.5 
5 V H 7 G H 4.5 
11 V HA 2 W HE3 4.5 
2 W HZ2 9 F QD 4.5 
10 T H 2 W HE3 4.5 
3 Q H 11 V HA 4.5 
10 T HA 11 V QQXG 4.5 
7 G H 6 P QB 4.5 
4 Y HA 8 K H 4.5 
10 T H 4 Y QD 4.5 
6 P QD 5 V H 4.5 
4 Y QE 9 F H 4.5 
3 Q H 12 Q H 4.5 
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Table A.4. (Continued) 
 
Residue Proton Residue Proton Distance 
3 Q HA 2 W HE3 4.5 
11 V HA 2 W HD1 4.5 
4 Y H 3 Q HG2 4.5 
7 G HA1 4 Y QE 5.5 
5 V QQXG 4 Y H 5.5 
10 T QXGT 12 Q H 5.5 
11 V QQXG 9 F QE 5.5 
10 T QXGT 5 V H 5.5 
4 Y QE 7 G HA1 5.5 
8 K QD 9 F H 5.5 
9 F H 10 T QXGT 5.5 
5 V HB 10 T QXGT 5.5 
11 V QQXG 2 W HD1 5.5 
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Table A.5. Peptide 3a NOE distance restraints. 
 
Residue Proton Residue Proton Residue 
2 W HA 3 X H 2.7 
4 Y HA 5 V H 2.7 
8 K HA 9 F H 2.7 
5 V HA 6 P HD2 2.7 
1 R HA 2 W H 2.7 
11 V HA 12 Q H 2.7 
5 V HA 6 P HD1 2.7 
3 X HA1 4 Y H 2.7 
6 P HD2 5 V HA 2.7 
2 W H 1 R HA 2.7 
12 Q H 11 V HA 2.7 
6 P HD1 5 V HA 2.7 
3 X H 2 W HA 2.7 
9 F HA 10 X H 2.7 
4 Y H 3 X HA2 2.7 
10 X H 9 F HA 2.7 
6 P HA 7 G H 2.7 
7 G HA2 8 K H 2.7 
3 X HA2 4 Y H 3.5 
7 G HA1 8 K H 3.5 
7 G H 6 P QG 3.5 
6 P QG 7 G H 3.5 
2 W QB 3 X H 3.5 
3 X H 2 W QB 3.5 
4 Y HA 9 F HA 3.5 
8 K H 7 G H 3.5 
8 K H 7 G HA1 3.5 
7 G H 8 K H 3.5 
12 Q H 12 Q HA 3.5 
11 V HB 12 Q H 3.5 
12 Q H 11 V HB 3.5 
6 P HD2 7 G H 3.5 
7 G H 6 P HD2 3.5 
4 Y HB2 5 V H 3.5 
9 F H 8 K H 3.5 
5 V H 4 Y HB2 3.5 
8 K HA 9 F QB 3.5 
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Table A.5 (Continued) 
 
Residue Proton Residue Proton Residue 
3 X HB 10 X HA2 3.5 
5 V QXG2 2 W HD1 3.5 
5 V QXG1 6 P HD1 3.5 
11 V HB 2 W QB 3.5 
9 F QB 10 X H 3.5 
9 F H 10 X H 3.5 
4 Y HA 10 X H 3.5 
12 Q H 11 V QQXG 4.5 
11 V QQXG 12 Q H 4.5 
2 W HA 3 X HB 4.5 
9 F HA 4 Y QD 4.5 
5 V HA 2 W QB 4.5 
5 V QXG1 6 P HD2 4.5 
10 X HA2 3 X HB 4.5 
3 X QQXD 4 Y H 4.5 
1 R QG 2 W H 4.5 
4 Y QD 9 F HA 4.5 
1 R HA 2 W QB 4.5 
4 Y QE 9 F QB 4.5 
5 V QXG2 6 P HD1 4.5 
2 W QB 5 V HA 4.5 
4 Y QD 5 V H 4.5 
7 G HA1 6 P HA 4.5 
7 G H 6 P HD1 4.5 
12 Q H 11 V H 4.5 
7 G HA2 6 P HA 4.5 
11 V H 12 Q H 4.5 
3 X HB 4 Y H 4.5 
6 P HD1 7 G H 4.5 
5 V HA 6 P HA 4.5 
6 P HD2 5 V H 4.5 
4 Y HB1 5 V H 4.5 
4 Y HB2 7 G H 4.5 
6 P QB 7 G H 4.5 
2 W HA 11 V H 4.5 
4 Y HB2 7 G HA2 4.5 
5 V H 4 Y HB1 4.5 
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Table A.5 (Continued) 
 
Residue Proton Residue Proton Residue 
4 Y HB1 7 G H 4.5 
3 X HB 2 W HA 4.5 
5 V H 7 G H 4.5 
4 Y HB1 7 G HA1 4.5 
6 P HD1 5 V H 4.5 
9 F QD 10 X H 4.5 
5 V H 4 Y H 4.5 
7 G H 4 Y HB2 4.5 
4 Y H 5 V H 4.5 
7 G HA1 4 Y HB2 4.5 
10 X HA1 9 F HA 4.5 
3 X HB 10 X H 4.5 
2 W HE3 3 X H 4.5 
11 V H 2 W HA 4.5 
3 X HG 4 Y H 4.5 
11 V H 2 W H 4.5 
9 F HA 5 V H 4.5 
10 X HB 9 F HA 4.5 
11 V HB 2 W H 4.5 
3 X QQXD 9 F QE 4.5 
5 V QXG2 2 W QB 4.5 
5 V QXG2 6 P HD2 4.5 
10 X H 9 F QD 4.5 
5 V HA 7 G H 4.5 
4 Y QD 8 K HA 4.5 
3 X HA2 2 W HD1 4.5 
7 G H 5 V HA 4.5 
2 W HA 1 R HA 4.5 
4 Y HB1 8 K H 4.5 
11 V QQXG 2 W QB 5.5 
3 X QQXD 4 Y QE 5.5 
3 X QQXD 4 Y QD 5.5 
3 X QQXD 2 W HA 5.5 
2 W QB 4 Y H 5.5 
5 V QXG2 2 W HE1 5.5 
1 R QD 2 W HE1 5.5 
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Table A.6. Peptide 9a NOE distance restraints. 
 
Residue Proton Residue Proton Residue 
6 P QD 5 V HA 2.7 
10 X H 9 F HA 2.7 
9 F HA 10 X H 2.7 
12 Q H 11 V HA 2.7 
11 V HA 12 Q H 2.7 
9 F H 8 K HA 2.7 
8 K HA 9 F H 2.7 
11 V H 10 X HA 2.7 
10 X HA 11 V H 2.7 
2 W H 1 R HA 2.7 
1 R HA 2 W H 2.7 
7 G HA1 7 G H 2.7 
4 Y HA 5 V H 2.7 
3 X HB 10 X HA 2.7 
7 G HA2 7 G H 2.7 
4 Y H 3 X QXE 3.5 
3 X QXE 4 Y H 3.5 
7 G H 8 K H 3.5 
8 K H 7 G H 3.5 
11 V H 2 W H 3.5 
11 V H 10 X QXD1 3.5 
10 X QXD1 11 V H 3.5 
5 V H 8 K H 3.5 
8 K H 5 V H 3.5 
4 Y HA 9 F HA 3.5 
7 G HA1 8 K H 3.5 
1 R QG 2 W H 3.5 
9 F H 8 K HB2 3.5 
8 K HB2 9 F H 3.5 
9 F HA 4 Y QD 3.5 
5 V H 4 Y HB2 3.5 
4 Y HB2 5 V H 3.5 
3 X HB 10 X H 3.5 
11 V H 10 X HB 3.5 
10 X HB 11 V H 3.5 
3 X HB 4 Y H 3.5 
10 X HG 11 V H 3.5 
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Table A.6. (Continued) 
 
Residue Proton Residue Proton Residue 
3 X HG 4 Y H 3.5 
9 F H 8 K HB1 3.5 
8 K HB1 9 F H 3.5 
11 V H 3 X HB 3.5 
3 X HB 11 V H 3.5 
9 F HB1 8 K HA 3.5 
11 V HA 10 X HG 3.5 
6 P QD 5 V QXG2 4.5 
4 Y QE 9 F HB1 4.5 
9 F HB1 4 Y QE 4.5 
8 K H 7 G HA2 4.5 
7 G HA2 8 K H 4.5 
9 F QD 3 X HG 4.5 
3 X HG 9 F QD 4.5 
10 X QXD1 5 V HB 4.5 
9 F QD 10 X QXE 4.5 
10 X QXE 9 F QD 4.5 
10 X QXE 3 X HB 4.5 
3 X QXE 2 W HE1 4.5 
2 W HA 3 X QXE 4.5 
10 X H 9 F QD 4.5 
9 F QD 10 X H 4.5 
4 Y QE 9 F HB2 4.5 
9 F HB2 4 Y QE 4.5 
10 X QXD1 9 F HA 4.5 
3 X HG 10 X QXE 4.5 
10 X QXE 9 F HA 4.5 
10 X HA 3 X QXE 4.5 
3 X QXE 10 X HA 4.5 
10 X H 9 F HB1 4.5 
9 F HB1 10 X H 4.5 
3 X QXE 2 W HB2 4.5 
5 V QXG2 6 P HA 4.5 
4 Y QD 3 X HG 4.5 
3 X HG 4 Y QD 4.5 
10 X H 9 F HB2 4.5 
9 F HB2 10 X H 4.5 
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Table A.6. (Continued) 
 
Residue Proton Residue Proton Residue 
4 Y QD 5 V H 4.5 
12 Q HA 1 R QG 4.5 
1 R QG 12 Q HA 4.5 
5 V H 4 Y HB1 4.5 
4 Y HB1 5 V H 4.5 
9 F HA 10 X HA 4.5 
10 X HA 9 F HA 4.5 
3 X QXE 2 W HZ2 4.5 
8 K H 6 P HA 4.5 
6 P HA 8 K H 4.5 
3 X HG 9 F HA 4.5 
5 V H 6 P QD 4.5 
6 P QD 5 V H 4.5 
9 F HA 5 V H 4.5 
10 X QXD1 2 W HE3 4.5 
9 F H 10 X H 4.5 
10 X H 9 F H 4.5 
9 F H 8 K HG1 4.5 
8 K HG1 9 F H 4.5 
10 X QXE 9 F HB1 4.5 
9 F H 8 K H 4.5 
8 K H 9 F H 4.5 
5 V H 4 Y H 4.5 
3 X QXE 2 W HB1 4.5 
1 R HE 12 Q HA 4.5 
9 F HB2 8 K HA 4.5 
5 V HB 8 K H 4.5 
3 X QXE 2 W HZ3 4.5 
5 V H 10 X H 4.5 
9 F H 8 K HG2 4.5 
8 K HG2 9 F H 4.5 
4 Y HB2 5 V HA 4.5 
4 Y QE 9 F HA 4.5 
3 X HG 4 Y QE 4.5 
12 Q HA 2 W H 4.5 
3 X HG 10 X H 4.5 
11 V H 10 X H 4.5 
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Table A.6. (Continued) 
 
Residue Proton Residue Proton Residue 
10 X H 11 V H 4.5 
3 X HG 10 X HA 4.5 
11 V H 2 W HB1 4.5 
11 V H 2 W HB2 4.5 
2 W HB2 11 V H 4.5 
2 W HE3 11 V H 4.5 
8 K H 4 Y QD 4.5 
4 Y QD 8 K H 4.5 
1 R HA 2 W HB2 4.5 
2 W HB2 1 R HA 4.5 
8 K H 4 Y HB2 4.5 
9 F HA 4 Y HB2 4.5 
4 Y HB2 9 F HA 4.5 
9 F HA 4 Y HB1 4.5 
1 R HE 2 W H 4.5 
8 K HG2 6 P HA 4.5 
1 R HE 12 Q H 4.5 
5 V QXG1 2 W HZ3 4.5 
12 Q HA 1 R QB 4.5 
1 R QB 12 Q HA 4.5 
10 X QXE 1 R QD 5.5 
3 X QXE 10 X H 5.5 
10 X QXE 11 V HA 5.5 
5 V QXG1 2 W HZ2 5.5 
5 V QXG1 4 Y H 5.5 
3 X QXE 11 V H 5.5 
10 X QXD1 11 V HA 5.5 
5 V QXG1 10 X H 5.5 
3 X QXE 4 Y HB1 5.5 
4 Y QE 9 F H 5.5 
4 Y HB2 6 P QD 5.5 
3 X QXE 2 W H 5.5 
4 Y QD 10 X H 5.5 
7 G HA1 6 P HA 5.5 
3 X QXE 5 V H 5.5 
6 P QD 5 V QXG1 5.5 
5 V QXG1 6 P QD 5.5 
111 
 
Table A.7. Peptide 10a NOE Distance Restraints 
 
Residue Proton Residue Proton Residue 
6 P QD 5 V HA 2.7 
9 F H 8 K HA 2.7 
8 K HA 9 F H 2.7 
10 X H 9 F HA 2.7 
11 V H 10 X HA 2.7 
12 Q H 11 V HA 2.7 
11 V HA 12 Q H 2.7 
7 G HA1 7 G H 2.7 
2 W H 1 R HA 2.7 
4 Y HA 5 V H 2.7 
7 G HA2 7 G H 2.7 
3 X HB 10 X QXD1 3.5 
7 G H 6 P HA 3.5 
6 P HA 7 G H 3.5 
10 X QXE 5 V HB 3.5 
7 G H 8 K H 3.5 
8 K H 7 G H 3.5 
2 W H 1 R QB 3.5 
5 V H 8 K H 3.5 
8 K H 5 V H 3.5 
3 X H 2 W QB 3.5 
2 W QB 3 X H 3.5 
4 Y HA 9 F HA 3.5 
7 G HA2 8 K H 3.5 
8 K H 7 G HA1 3.5 
4 Y H 3 X HG 3.5 
3 X HG 4 Y H 3.5 
9 F H 8 K HB2 3.5 
8 K HB2 9 F H 3.5 
5 V H 4 Y HB1 3.5 
11 V H 10 X HG 3.5 
10 X HG 11 V H 3.5 
4 Y H 3 X QXD2 4.5 
3 X QXD2 4 Y H 4.5 
3 X QXD1 10 X HA 4.5 
3 X HG 5 V QXG1 4.5 
5 V QXG1 3 X HG 4.5 
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Table A.7. (Continued) 
 
Residue Proton Residue Proton Residue 
11 V H 10 X QXE 4.5 
10 X QXE 11 V H 4.5 
3 X HG 10 X QXE 4.5 
2 W QB 11 V HB 4.5 
11 V HB 2 W QB 4.5 
11 V H 10 X QXD1 4.5 
10 X QXD1 11 V H 4.5 
7 G HA1 8 K H 4.5 
6 P QD 5 V HB 4.5 
7 G H 6 P QD 4.5 
6 P QD 7 G H 4.5 
5 V H 10 X QXE 4.5 
10 X QXE 5 V H 4.5 
3 X QXD1 2 W QB 4.5 
4 Y HB1 5 V H 4.5 
11 V H 3 X QXD1 4.5 
3 X QXD1 11 V H 4.5 
11 V QXG2 12 Q H 4.5 
10 X QXD1 1 R QD 4.5 
10 X QXD1 12 Q HA 4.5 
4 Y H 3 X HB 4.5 
3 X HB 4 Y H 4.5 
2 W HA 3 X HA 4.5 
12 Q H 11 V H 4.5 
11 V H 12 Q H 4.5 
1 R HA 2 W QB 4.5 
2 W HA 3 X QXD2 4.5 
5 V H 6 P QD 4.5 
6 P QD 5 V H 4.5 
2 W HD1 3 X H 4.5 
4 Y HA 10 X H 4.5 
3 X QXD2 2 W HD1 4.5 
10 X QXD1 1 R HG1 4.5 
2 W H 3 X H 4.5 
3 X QXD1 4 Y H 4.5 
9 F H 8 K HB1 4.5 
8 K HB1 9 F H 4.5 
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Table A.7. (Continued) 
 
Residue Proton Residue Proton Residue 
2 W H 1 R HG1 4.5 
1 R HG1 2 W H 4.5 
5 V H 9 F HA 4.5 
9 F HA 5 V H 4.5 
7 G H 4 Y HB1 4.5 
4 Y HB1 7 G H 4.5 
10 X QXD2 12 Q HA 4.5 
3 X HG 5 V H 4.5 
2 W H 1 R HG2 4.5 
1 R HG2 2 W H 4.5 
8 K H 6 P HA 4.5 
6 P HA 8 K H 4.5 
8 K H 4 Y HB1 4.5 
6 P HB2 7 G H 4.5 
8 K HB1 5 V H 4.5 
7 G H 5 V HA 4.5 
5 V HA 7 G H 4.5 
9 F H 4 Y QE 4.5 
4 Y QE 9 F H 4.5 
8 K HG2 9 F H 4.5 
9 F H 8 K H 4.5 
8 K H 9 F H 4.5 
5 V H 4 Y HB2 4.5 
4 Y HB2 5 V H 4.5 
7 G HA2 6 P HA 4.5 
8 K HG1 9 F H 4.5 
8 K HA 4 Y QE 4.5 
5 V H 4 Y H 4.5 
4 Y H 5 V H 4.5 
10 X H 9 F H 4.5 
2 W H 11 V H 4.5 
11 V H 2 W H 4.5 
7 G H 4 Y HB2 4.5 
11 V HB 2 W HE3 4.5 
10 X HG 12 Q H 4.5 
10 X H 5 V H 4.5 
8 K H 4 Y HB2 4.5 
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Table A.7. (Continued) 
 
Residue Proton Residue Proton Residue 
10 X QXE 3 X QXD1 5.5 
10 X QXE 8 K QD 5.5 
4 Y HB1 8 K H 5.5 
11 V QXG2 2 W HE3 5.5 
5 V QXG1 10 X H 5.5 
3 X QXD1 11 V HB 5.5 
10 X QXD2 9 F HB2 5.5 
12 Q H 11 V QXG1 5.5 
11 V QXG1 12 Q H 5.5 
10 X QXD1 1 R HG2 5.5 
11 V QXG1 2 W HE3 5.5 
10 X QXD1 2 W H 5.5 
3 X QXD2 2 W HE3 5.5 
3 X QXD1 2 W HZ2 5.5 
3 X QXD2 2 W HZ2 5.5 
11 V HA 10 X QXD1 5.5 
5 V QXG1 4 Y H 5.5 
10 X QXD2 9 F HB1 5.5 
8 K QD 9 F H 5.5 
3 X QXD1 2 W HE3 5.5 
4 Y HB1 6 P QD 5.5 
10 X QXD1 12 Q H 5.5 
11 V H 10 X QXD2 5.5 
10 X QXD2 11 V H 5.5 
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